,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,192,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,204,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia resistant to methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,206,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
3,212,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
4,220,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
5,224,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P335 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
6,230,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice,Other,,
7,236,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  AK4 Lymphoid Leukemia (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
8,238,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Leiomyosarcoma (No. 2) (intraperitoneal) in CAF1 mice,Other,,
9,240,1,1,,75254,5755,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 4 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
10,248,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
11,250,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
12,256,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
13,266,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
14,268,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice,Other,,
15,270,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
16,276,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
17,282,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
18,284,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
19,290,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in unknown mice,Other,,
20,296,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
21,304,1,1,,75254,5755,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Mecca (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
22,306,1,1,,75254,5755,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
23,312,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  C1498 Myeloid Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
24,316,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
25,320,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P329 Reticulum Cell Sarcoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
26,328,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
27,330,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
28,332,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-20 Plasma Cell (subcutaneous) in unknown mice,Other,,
29,336,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
30,338,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
31,340,1,1,,75254,5755,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Reticulum Cell Sarcoma (Kelley Mouse) (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
32,377,1,3,,10321429,5755,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
33,1189,1,5,,48414366,5755,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
34,1194,1,3,,48414366,5755,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
35,1195,1,2,,48416460,5755,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
36,1208,1,3,,48414366,5755,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
37,1332,1,1,,49698415,5755,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
38,1490,2,1,,50085972,5755,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
39,1511,1,3,,50085972,5755,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
40,1527,1,3,,50085972,5755,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
41,1529,1,1,,50085972,5755,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
42,1530,1,1,,50085972,5755,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
43,1531,1,1,,50085972,5755,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
44,1554,1,1,,50085972,5755,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
45,1556,1,4,,50085972,5755,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
46,1565,2,2,,50085972,5755,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
47,1566,2,3,,50085972,5755,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
48,1578,3,2,,50085972,5755,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
49,1621,1,2,,50085972,5755,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
50,1631,3,1,,50085972,5755,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
51,1634,3,1,,50085972,5755,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
52,1654,2,2,,50085972,5755,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
53,1656,2,2,,50085972,5755,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
54,1662,1,2,,50085972,5755,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
55,1663,1,2,,50085972,5755,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
56,1672,1,3,,50085972,5755,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
57,1700,1,2,,50085972,5755,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
58,1706,1,2,,50085972,5755,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
59,1721,1,2,,50085972,5755,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
60,1722,1,2,,50085972,5755,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
61,1766,1,1,,50085972,5755,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
62,1766,1,1,,50085972,5755,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
63,1768,1,1,,50085972,5755,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
64,1768,1,1,,50085972,5755,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
65,1777,3,2,,50085972,5755,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
66,1778,3,3,,50085972,5755,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
67,1779,2,2,,50085972,5755,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
68,1789,1,2,,50085972,5755,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
69,1800,1,2,,50085972,5755,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
70,1813,1,2,,50085972,5755,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
71,1814,1,2,,50085972,5755,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
72,1817,2,2,,50085972,5755,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
73,1822,1,3,,50085972,5755,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
74,1825,1,1,,50085972,5755,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
75,1832,2,1,,50085972,5755,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
76,1845,1,2,,50085972,5755,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
77,1850,2,1,,50085972,5755,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
78,1861,2,1,,50085972,5755,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
79,1863,2,1,,50085972,5755,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
80,1875,2,1,,50085972,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
81,1885,2,1,,50085972,5755,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
82,1899,1,3,,50085972,5755,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
83,1903,2,3,,50085972,5755,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
84,1906,1,3,,50085972,5755,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
85,1910,1,2,,50085972,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
86,1947,1,2,,50085972,5755,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
87,1950,1,3,,50085972,5755,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
88,1961,2,2,,50085972,5755,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
89,1962,1,2,,50085972,5755,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
90,1974,1,2,,50085972,5755,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
91,1984,1,3,,50085972,5755,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
92,1986,1,2,,50085972,5755,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
93,1987,1,2,,50085972,5755,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
94,2006,3,2,,50085972,5755,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
95,2006,3,2,,50085972,5755,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
96,2006,3,2,,50085972,5755,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
97,2012,3,2,,50085972,5755,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
98,2013,2,2,,50085972,5755,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
99,2014,3,2,,50085972,5755,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
100,2016,1,3,,50085972,5755,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
101,2023,1,3,,50085972,5755,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
102,2025,1,3,,50085972,5755,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
103,2029,1,3,,50085972,5755,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
104,2052,2,1,,50085972,5755,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
105,2057,1,2,,50085972,5755,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
106,2058,3,2,,50085972,5755,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
107,2066,1,4,,50085972,5755,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
108,2071,2,2,,50085972,5755,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
109,2073,2,3,,50085972,5755,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
110,2073,2,3,,50085972,5755,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
111,2094,1,2,,50085972,5755,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
112,2094,1,2,,50085972,5755,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
113,2094,1,2,,50085972,5755,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
114,2097,1,2,,50085972,5755,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
115,2098,1,1,,50085972,5755,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
116,2099,1,1,,50085972,5755,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
117,2100,1,1,,50085972,5755,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
118,2101,1,1,,50085972,5755,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
119,2129,1,2,,50085972,5755,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
120,2130,1,3,,50085972,5755,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
121,2156,2,2,,50085972,5755,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
122,2174,1,3,,50085972,5755,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
123,2177,1,3,,50085972,5755,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
124,2216,1,3,,50085972,5755,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
125,2221,1,2,,50085972,5755,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
126,2227,1,2,,50085972,5755,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
127,2234,1,2,,50085972,5755,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
128,2235,1,2,,50085972,5755,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
129,2237,1,2,,50085972,5755,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
130,2239,1,2,,50085972,5755,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
131,2240,1,1,,85788424,5755,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
132,2241,1,1,,85788424,5755,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
133,2247,1,2,,50085972,5755,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
134,2275,1,1,,85788424,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
135,2280,2,3,,50085972,5755,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
136,2288,1,1,,50085972,5755,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
137,2289,1,1,,50085972,5755,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
138,2300,1,3,,50085972,5755,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
139,2313,1,1,,85788424,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
140,2314,1,2,,50085972,5755,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
141,2314,1,2,,50085972,5755,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
142,2315,1,2,,50085972,5755,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
143,2315,1,2,,50085972,5755,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
144,2322,1,1,,85788424,5755,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
145,2326,1,1,,50085972,5755,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
146,2330,1,1,,85788424,5755,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
147,2380,1,2,,50085972,5755,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
148,2382,1,1,,50085972,5755,Inconclusive,62740231.0,15499.0,,EC50,Luminescence Cell-Based  Dose Confimation HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1),Confirmatory,,
149,2391,1,1,,50085972,5755,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
150,2435,1,2,,50085972,5755,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
151,2445,1,2,,50085972,5755,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
152,2451,1,2,,50085972,5755,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
153,2462,1,1,,50085972,5755,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
154,2462,1,1,,50085972,5755,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
155,2472,1,2,,50085972,5755,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
156,2517,2,1,,50085972,5755,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
157,2517,2,1,,144204880,5755,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
158,2520,1,4,,50085972,5755,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
159,2521,1,3,,50085972,5755,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
160,2524,1,2,,50085972,5755,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
161,2528,1,2,,50085972,5755,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
162,2540,1,2,,50085972,5755,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
163,2544,1,2,,50085972,5755,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
164,2546,1,1,,50085972,5755,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
165,2550,1,3,,50085972,5755,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
166,2551,1,1,,50085972,5755,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
167,2553,1,2,,50085972,5755,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
168,2557,1,3,,50085972,5755,Active,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
169,2563,1,1,,50085972,5755,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
170,2599,1,2,,50085972,5755,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
171,2606,1,2,,50085972,5755,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
172,2629,1,1,,50085972,5755,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
173,2642,1,2,,50085972,5755,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
174,2648,1,2,,50085972,5755,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
175,2650,2,1,,50085972,5755,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
176,2661,1,1,,50085972,5755,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
177,2662,2,1,,50085972,5755,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
178,2675,1,1,,50085972,5755,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
179,2676,1,2,,50085972,5755,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
180,2685,1,1,,50085972,5755,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
181,2690,1,2,,50085972,5755,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
182,2716,1,1,,50085972,5755,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
183,2717,1,2,,50085972,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
184,2718,1,1,,50085972,5755,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
185,2751,2,2,,50085972,5755,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
186,2796,1,4,,50085972,5755,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
187,2797,1,2,,50085972,5755,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
188,2805,2,2,,50085972,5755,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
189,2806,2,2,,50085972,5755,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
190,2813,1,2,,50085972,5755,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from Cherry Picked Plates,Screening,,
191,2825,1,2,,50085972,5755,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
192,7783,3,4,,103189031,5755,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
193,8002,5,2,,103189031,5755,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
194,8455,5,6,,103189031,5755,Active,121069.0,2908.0,0.0045,EC50,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Confirmatory,15115388.0,
195,19424,3,4,,103189031,5755,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
196,19427,3,3,,103189031,5755,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
197,21087,4,3,,103189031,5755,Unspecified,,,,,Octanol- water partition coefficient was determined.,Other,3681894.0,
198,21993,5,2,,103189031,5755,Unspecified,,,,,Water solubility was determined,Other,14736251.0,
199,22293,4,4,,103189031,5755,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
200,24428,3,3,,103189031,5755,Unspecified,,,,,Partition coefficient (logP),Other,3965714.0,
201,26304,4,4,,103189031,5755,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
202,26380,3,3,,103189031,5755,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
203,27580,3,3,,103189031,5755,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
204,28233,3,3,,103189031,5755,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
205,28235,3,3,,103189031,5755,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
206,28236,3,3,,103189031,5755,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
207,29360,4,3,,103189031,5755,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
208,29421,3,3,,103189031,5755,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
209,29423,3,4,,103189031,5755,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
210,29811,4,3,,103189031,5755,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
211,29925,5,2,,103189031,5755,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
212,39148,8,5,,103189031,5755,Active,1018618719.0,367.0,2.762,Ki,Binding affinity for androgen receptor,Confirmatory,11520196.0,
213,47188,5,6,,103189031,5755,Active,121069.0,2908.0,0.008,EC50,Transcriptional activation in CV-1 cells expressing human glucocorticoid receptor,Confirmatory,12620078.0,
214,47197,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transcriptional activation in CV-1 cells expressing human glucocorticoid receptor compared to Dexamethasone,Other,12620078.0,
215,47366,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Repression of transcriptional activity in CV-1 cells expressing glucocorticoid receptor compared to Dexamethasone,Other,15026058.0,
216,47367,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transcriptional activation in CV-1 cells expressing glucocorticoid receptor compared to Dexamethasone,Other,15026058.0,
217,47368,5,6,,103189031,5755,Active,121069.0,2908.0,0.008,IC50,Inhibition of transcriptional activation in CV-1 cells expressing glucocorticoid receptor,Confirmatory,15026058.0,
218,47369,5,6,,103189031,5755,Active,121069.0,2908.0,0.0021,IC50,Inhibition of transcriptional repression in CV-1 cells expressing glucocorticoid receptor,Confirmatory,15026058.0,
219,47370,4,6,,103189031,5755,Unspecified,,,,,Efficacy expressed relative to maximal response produced by Dex for GRE activation.,Other,11728194.0,
220,47372,4,6,,103189031,5755,Active,,,0.0033,EC50,The effective concentration in CV-1 cells for glucocorticoid response element activation (GRE).,Confirmatory,11728194.0,
221,51048,3,7,,103189031,5755,Unspecified,,,,,In silico binding affinity to human corticosteriod binding globulin,Other,9379435.0,
222,51049,3,7,,103189031,5755,Unspecified,,,,,Binding affinity against corticosteroid-binding globulin,Other,8474098.0,
223,51052,3,7,,103189031,5755,Unspecified,,,,,In silico binding affinity to corticosteroid binding globulin (CBG),Other,9435904.0,
224,51053,3,7,,103189031,5755,Unspecified,,,,,Compound was evaluated for its binding affinity towards the human corticosteroid binding globulin,Other,10052964.0,
225,51054,3,7,,103189031,5755,Unspecified,,,,,Binding affinity for corticosteroid binding globulin is expressed as log(1/k),Other,8667357.0,
226,51055,4,1,,103189031,5755,Active,,,0.0309,Ki,Binding affinity to human CBG receptor (corticosteroid-binding globulins),Confirmatory,15139751.0,
227,51058,3,7,,103189031,5755,Unspecified,,,,,Binding affinity towards corticosteroid-binding globulin (CBG),Other,12672239.0,
228,51059,3,7,,103189031,5755,Unspecified,,,,,Binding affinity to corticosteroid binding globulin,Other,9651159.0,
229,51062,3,8,,103189031,5755,Unspecified,,,,,In silico steroid binding affinity to transport protein corticosteroid binding globulin,Other,8057280.0,
230,53571,5,6,,103189031,5755,Active,121069.0,2908.0,0.040999999999999995,IC50,Glucocorticoid-induced aromatase activity in human skin fibroblasts,Confirmatory,11520196.0,
231,53796,4,4,,103189031,5755,Unspecified,,,,,Binding affinity to the corticosteroid-binding globulin (CBG) receptor.,Other,10966742.0,
232,54050,3,12,,103189031,5755,Unspecified,121069.0,2908.0,,,Glucocorticoid-induced aromatase activity in human skin fibroblasts compared to Dexamethasone,Other,11520196.0,
233,55274,4,3,,103189031,5755,Active,,,0.1963,IC50,Concentration of compound required to inhibit the binding of 28 nM [3H]dexamethasone by 50% to rat hepatic cytosolic receptors,Confirmatory,3681894.0,
234,69856,4,6,,103189031,5755,Unspecified,,,1.0,Ki,Binding affinity towards estradiol receptor (Estrogen receptor),Confirmatory,12620078.0,
235,70976,4,12,,103189031,5755,Unspecified,544257.0,2099.0,1.0,Ki,Binding affinity for estrogen receptor,Confirmatory,11520196.0,
236,70976,4,12,,103189031,5755,Unspecified,6166154.0,2100.0,1.0,Ki,Binding affinity for estrogen receptor,Confirmatory,11520196.0,
237,73767,3,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Inhibition of [3H]dexamethasone binding to glucocorticoid receptor of human blood mononuclear cells,Other,14736251.0,
238,73768,4,8,,103189031,5755,Active,,,,,In vitro binding affinity against human glucocorticoid receptor (GR),Other,15026058.0,
239,73771,3,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Displacement of [3H]dexamethasone from glucocorticoid receptor of human blood mononuclear cells at 1 uM,Other,14736251.0,
240,74078,8,5,,103189031,5755,Active,121069.0,2908.0,0.0138,IC50,Inhibition of human Glucocorticoid receptor,Confirmatory,15115388.0,
241,74083,5,6,,103189031,5755,Active,121069.0,2908.0,0.008,IC50,Transcriptional activation in CV-1 cells expressing glucocorticoid receptor,Confirmatory,11520196.0,
242,74225,7,2,,103189031,5755,Active,,,0.0024,Ki,Binding affinity towards glucocorticoid receptor (GR) by displacing [3H]dexamethasone,Confirmatory,11728194.0,
243,74226,7,1,,103189031,5755,Active,,,0.0024,Ki,Binding affinity towards human glucocorticoid receptor (GR) was determined using [3H]dexamethasone as radioligand in SF-1 cells,Confirmatory,12620078.0,
244,74232,8,5,,103189031,5755,Active,121069.0,2908.0,0.0024,Ki,Binding affinity for glucocorticoid receptor,Confirmatory,11520196.0,
245,74239,3,12,,103189031,5755,Unspecified,121069.0,2908.0,,,Transcriptional activation in CV-1 cells expressing glucocorticoid receptor compared to Dexamethasone,Other,11520196.0,
246,74963,7,1,,103189031,5755,Active,,,0.032,EC50,Ability to induce human glutamine synthetase in skeletal muscle cells,Confirmatory,15115388.0,
247,81481,6,2,,103189031,5755,Active,,,0.76,IC50,Inhibitory concentration against interleukin-1 beta production in HL-60 cells stimulated with lipopolysaccharide (LPS).,Confirmatory,11527734.0,
248,81482,6,2,,103189031,5755,Active,,,0.76,IC50,Inhibitory concentration against interleukin-1 beta production in HL-60 cells stimulated with lipopolysaccharide (LPS).,Confirmatory,11527733.0,
249,81558,5,6,,103189031,5755,Active,121069.0,2908.0,0.0021,EC50,Transcriptional repression in HepG2 cells expressing human glucocorticoid receptor,Confirmatory,12620078.0,
250,81559,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transcriptional repression in HepG2 cells expressing human glucocorticoid receptor compared to Dexamethasone,Other,12620078.0,
251,86562,4,6,,103189031,5755,Unspecified,,,,,Efficacy relative to maximal response produced by Dex for E-selectin repression.,Other,11728194.0,
252,86563,4,6,,103189031,5755,Active,,,0.0026,EC50,Effective concentration in HepG2 cells transfected with LUC gene (E-sel-Luc).,Confirmatory,11728194.0,
253,90104,5,1,,103189031,5755,Unspecified,,,,,"Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test",Other,6827553.0,
254,90303,4,4,,103189031,5755,Active,,,0.045,EC50,Effective concentration for transcriptional activation of aromatase in Human cell native protein assay,Confirmatory,15026058.0,
255,90304,4,4,,103189031,5755,Active,,,0.0036,EC50,Effective concentration of compound for transcriptional activation of IL-6 in Human cell native protein assay,Confirmatory,15026058.0,
256,90305,4,4,,103189031,5755,Active,,,0.002,EC50,Effective concentration of compound for transcriptional activation of PGE-2 in Human cell native protein assay,Confirmatory,15026058.0,
257,90307,4,4,,103189031,5755,Active,,,0.048,EC50,Effective concentration of compound for transcriptional activation of TAT in Human cell native protein assay,Confirmatory,15026058.0,
258,90421,4,4,,103189031,5755,Active,,,0.0004,EC50,Effective concentration of compound for transcriptional activation of collagenase in Human cell native protein assay,Confirmatory,15026058.0,
259,90422,4,4,,103189031,5755,Active,,,0.032,EC50,Effective concentration of compound for transcriptional activation of osteocalcin in Human cell native protein assay,Confirmatory,15026058.0,
260,90425,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of IL-6 in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
261,90426,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of PGE-2 in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
262,90428,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of TAT in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
263,90429,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of aromatase in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
264,90430,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of collagenase in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
265,90431,3,5,,103189031,5755,Unspecified,,,,,Efficacy for transcriptional activation of osteocalcin in Human cell native protein assay expressed as percentage of the maximal response of Dexamethasone,Other,15026058.0,
266,91224,4,3,,103189031,5755,Inactive,,,,,Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay,Other,3783574.0,
267,91481,4,7,,103189031,5755,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
268,91902,5,6,,103189031,5755,Active,121069.0,2908.0,0.0038,IC50,Repression activity of GR ligand with interleukin-6 receptor in native cell assay using Dexamethasone was determined as maximal potency,Confirmatory,11520196.0,
269,91903,4,12,,103189031,5755,Unspecified,121069.0,2908.0,,,Repression activity of GR ligand with interleukin-6 receptor in native cell assay using Dexamethasone was determined as percentage efficacy,Other,11520196.0,
270,102827,4,3,,103189031,5755,Unspecified,,,,,Compound (0.10 ug/mL) was tested for their immunomodulatory activity in vitro using mixed lymphocyte reaction,Other,10866376.0,
271,115391,3,3,,103189031,5755,Unspecified,,,,,Percent inhibition of anti-DNA antibody was evaluated by ELISA technique as a measure of auto-immune disease after injection of compound dose of 0.1 mg/kg in murine,Other,11738579.0,
272,115394,3,3,,103189031,5755,Unspecified,,,,,Percent inhibition of anti-DNA antibody was evaluated by ELISA technique as a measure of auto-immune disease after injection of compound dose of 1 mg/kg in murine,Other,11738579.0,
273,115396,4,2,,103189031,5755,Unspecified,,,,,Percent inhibition of anti-DNA antibody was evaluated by ELISA technique as a measure of auto-immune disease after injection of compound dose of 10 mg/kg in murine,Other,11738579.0,
274,115541,3,3,,103189031,5755,Unspecified,,,,,Percent inhibition of proteinuria by compound dose of 0.1 mg/kg given perorally to murine in chronic graft-versus-host-disease test,Other,11738579.0,
275,115545,3,3,,103189031,5755,Unspecified,,,,,Percent inhibition of proteinuria by compound dose of 1 mg/kg given perorally to murine in chronic graft-versus-host-disease test,Other,11738579.0,
276,115547,3,3,,103189031,5755,Unspecified,,,,,Percent inhibition of proteinuria by compound dose of 10 mg/kg given perorally to murine in chronic graft-versus-host-disease test,Other,11738579.0,
277,126442,6,2,,103189031,5755,Active,,,0.037000000000000005,Ki,Binding affinity towards aldosterone receptor (Mineralocorticoid receptor),Confirmatory,12620078.0,
278,127633,4,3,,103189031,5755,Active,,,0.0057,EC50,Ability to induce mouse macrophage IL-6 assay in peritoneal exudate cells harvested by gavage from C57BI/6 mice.,Confirmatory,15115388.0,
279,133427,3,3,,103189031,5755,Unspecified,,,,,"Acute lethal toxicity (peroral administration), determined by observing the mortality for 7 days after the administration in mouse",Other,1495017.0,
280,136368,3,3,,103189031,5755,Inactive,,,,,Observation of behavior in mice following 30 mg/kg i.p. administration; No significant change.,Other,11527733.0,
281,140313,3,3,,103189031,5755,Unspecified,,,,,Compound was tested for the immunomodulatory activity in vitro expressed as stimulation index by lymphocyte transformation test at 0.1 ug/mL,Other,9871679.0,
282,155103,5,6,,103189031,5755,Active,121069.0,2908.0,0.025,EC50,Inhibition of concanavalin A stimulated T-cell proliferation in human PBMCs,Confirmatory,12620078.0,
283,155128,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Inhibition of concanavalin A stimulated T-cell proliferation in human PBMCs compared to Dexamethasone,Other,12620078.0,
284,156392,7,2,,103189031,5755,Unspecified,,,5.0,Ki,Binding affinity towards progesterone receptor (PR) by displacing [3H]progesterone.,Confirmatory,11728194.0,
285,161463,3,5,,103189031,5755,Unspecified,,,,,"Bronchoalveolar lavages was collected after 48 hr (for eosinophil influx, eos) at 1 mg/kg dose",Other,10956206.0,
286,161466,3,5,,103189031,5755,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 1 mg/kg dose (for IL-5),Other,10956206.0,
287,161613,3,5,,103189031,5755,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 1 mg/kg dose (for IL-8),Other,10956206.0,
288,161614,3,5,,103189031,5755,Unspecified,,,,,Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 1 mg/kg dose (for eotaxin),Other,10956206.0,
289,161621,3,4,,103189031,5755,Unspecified,,,,,Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 10 min at 1 mg/kg dose,Other,10956206.0,
290,161624,3,4,,103189031,5755,Unspecified,,,,,Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 6 hour at 1 mg/kg dose,Other,10956206.0,
291,162463,4,8,,103189031,5755,Unspecified,,,,,In vitro binding affinity against progesterone receptor,Other,15026058.0,
292,162468,8,5,,103189031,5755,Unspecified,90110048.0,5241.0,5.0,Ki,Displacement of [3H]progesterone from human Progesterone receptor A,Confirmatory,12620078.0,
293,171191,3,3,,103189031,5755,Unspecified,,,,,The body weight change of rats after administration of the compound,Other,7699698.0,
294,171195,4,4,,103189031,5755,Unspecified,,,,,Compound was evaluated for antiinflammatory activity in granuloma bioassay and measured as body weight gain,Other,3681894.0,
295,171540,2,4,,103189031,5755,Unspecified,,,,,Cartilage space narrowing was measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
296,178273,6,2,,103189031,5755,Unspecified,,,,,Anti-asthmatic effect as eosinophil influx in rat lung model,Other,11520196.0,
297,180216,2,4,,103189031,5755,Unspecified,,,,,Erosions of tarsal bones measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
298,182857,3,3,,103189031,5755,Unspecified,,,,,Adjuvant arthritic activity in rat injected leg on day 16 tested at 20 mg/kg perorally.,Other,6690686.0,
299,182860,3,3,,103189031,5755,Unspecified,,,,,Adjuvant arthritic activity in rat injected leg on day 3 tested at 50 mg/kg perorally,Other,6690686.0,
300,182980,3,3,,103189031,5755,Unspecified,,,,,Adjuvant arthritic activity in rat uninjected leg on day 16 tested at 20 mg/kg perorally.,Other,6690686.0,
301,184569,4,3,,103189031,5755,Unspecified,,,,,Tested for inhibition of formation of granulation tissue around the cotton pellet treated with steroid,Other,3681894.0,
302,184570,4,3,,103189031,5755,Unspecified,,,,,Tested for inhibition of formation of granulation tissue around the cotton pellet untreated with steroid,Other,3681894.0,
303,184943,4,3,,103189031,5755,Unspecified,,,,,Tested for topical antiinflammatory activity in the croton oil ear edema assay,Other,3681894.0,
304,185115,3,3,,103189031,5755,Unspecified,,,,,The antiinflammatory activity was evaluated as %inhibition of croton oil induced ear edema in the left ear of rat,Other,7699698.0,
305,185118,3,3,,103189031,5755,Unspecified,,,,,The antiinflammatory activity was evaluated as %inhibition of croton oil induced ear edema in the right ear of rat,Other,7699698.0,
306,186886,4,4,,103189031,5755,Unspecified,,,,,Tested for topical antiinflammatory activity in the croton oil ear edema assay and was expressed as mean change in ear thickness of rats,Other,3681894.0,
307,186888,2,4,,103189031,5755,Unspecified,,,,,Paw diameter measured with a micrometer caliper after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
308,187403,4,3,,103189031,5755,Unspecified,,,,,Compound was evaluated for antiinflammatory activity in granuloma bioassay and measured as plasma corticosterone weight,Other,3681894.0,
309,187530,3,4,,103189031,5755,Unspecified,,,,,The plasma corticosterone (ng/ml) concentration was measured in rats after compound administration,Other,7699698.0,
310,187585,3,3,,103189031,5755,Unspecified,,,,,Recovery of steroid from cecum at 3h after administration of 7.5 mg of the compound,Other,6699871.0,
311,187586,3,3,,103189031,5755,Unspecified,,,,,Recovery of steroid from cecum at 4 hr after administration of 7.5 mg of the compound,Other,6699871.0,
312,187587,3,3,,103189031,5755,Unspecified,,,,,Recovery of steroid from cecum at 5 hr after administration of 7.5 mg of the compound,Other,6699871.0,
313,187588,3,3,,103189031,5755,Unspecified,,,,,Recovery of steroid from cecum at 6 hr after administration of 7.5 mg of the compound,Other,6699871.0,
314,187589,3,4,,103189031,5755,Unspecified,,,,,Recovery of steroid from small intestine at 3h after administration of 7.5 mg of the compound,Other,6699871.0,
315,187590,3,4,,103189031,5755,Unspecified,,,,,Recovery of steroid from small intestine at 4 hr after administration of 7.5 mg of the compound,Other,6699871.0,
316,187591,3,4,,103189031,5755,Unspecified,,,,,Recovery of steroid from small intestine at 5 hr after administration of 7.5 mg of the compound,Other,6699871.0,
317,187592,3,4,,103189031,5755,Unspecified,,,,,Recovery of steroid from small intestine at 6 hr after administration of 7.5 mg of the compound,Other,6699871.0,
318,187644,4,3,,103189031,5755,Unspecified,,,,,Evaluated for antiinflammatory activity in granuloma bioassay and expressed as relative thymus weight,Other,3681894.0,
319,188016,4,1,,103189031,5755,Unspecified,,,,,"Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate",Other,6827553.0,
320,188436,4,3,,103189031,5755,Unspecified,,,,,Tested for inhibition of formation of granulation tissue around the cotton pellet treated with steroid and expressed as net dry weight,Other,3681894.0,
321,188437,4,3,,103189031,5755,Unspecified,,,,,Tested for inhibition of formation of granulation tissue around the cotton pellet untreated with steroid and expressed as net dry weight,Other,3681894.0,
322,189704,4,3,,103189031,5755,Unspecified,,,,,Evaluated for antiinflammatory activity in granuloma bioassay and expressed as relative adrenal weight,Other,3681894.0,
323,190480,3,3,,103189031,5755,Unspecified,,,,,The thymus weight change of rats after administration of the compound,Other,7699698.0,
324,191933,3,3,,103189031,5755,Unspecified,,,,,Cutaneous oxazolone induced contact sensitivity in mouse and percent stimulation in right hind paw was determined at a dose 20 mg/kg perorally,Other,6690686.0,
325,202433,5,6,,103189031,5755,Active,121069.0,2908.0,0.0021,IC50,Transcriptional repression activity in HEP G2 cells expressing glucocorticoid receptor compared to Dexamethasone,Confirmatory,11520196.0,
326,202557,3,12,,103189031,5755,Unspecified,121069.0,2908.0,,,Transcriptional repression activity in HEP G2 cells expressing glucocorticoid receptor compared to Dexamethasone,Other,11520196.0,
327,204332,5,6,,103189031,5755,Active,1169883.0,24413.0,0.0196,EC50,Inhibition of concanavalin A stimulated rat splenocyte proliferation,Confirmatory,12620078.0,
328,204333,3,11,,103189031,5755,Unspecified,1169883.0,24413.0,,,Inhibition of concanavalin A stimulated rat splenocyte proliferation compared to Dexamethasone,Other,12620078.0,
329,212921,8,5,,103189031,5755,Active,1018618719.0,367.0,2.76,Ki,Binding affinity towards testosterone receptor,Confirmatory,12620078.0,
330,213397,5,6,,103189031,5755,Active,121069.0,2908.0,0.21100000000000002,EC50,Glucocorticoid induced transactivation of human tyrosine amino transferase in HepG2 cells,Confirmatory,15115388.0,
331,223722,3,3,,103189031,5755,Unspecified,,,,,Activity against arthritis on adjuvant-untreated paw in rats at 5 mg/kg by oral administration,Other,1469696.0,
332,223737,6,1,,103189031,5755,Unspecified,,,,,The compound was tested for IL-1 generation on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
333,223738,6,1,,103189031,5755,Unspecified,,,,,The compound was tested for IL-1 generation on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
334,223904,3,3,,103189031,5755,Unspecified,,,,,The compound was tested for Granuloma generation on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
335,223905,3,3,,103189031,5755,Unspecified,,,,,The compound was tested for Granuloma generation on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
336,224061,3,3,,103189031,5755,Unspecified,,,,,% inhibition against arthritis on adjuvant-untreated paw in rats at 5 mg/kg by oral administration,Other,1469696.0,
337,224207,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against Granuloma on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
338,224208,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against Granuloma on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
339,224210,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against IL-1 on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
340,224211,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against IL-1 on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
341,224213,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against PGE-2 on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
342,224214,3,3,,103189031,5755,Unspecified,,,,,Inhibitory activity against PGE-2 on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
343,224991,3,3,,103189031,5755,Unspecified,,,,,"Dose of the compound (oral administration) showing antiinflammatory effect on rat paw edema model (carrageenan-induced paw edema, CPE)",Other,1495017.0,
344,224992,3,3,,103189031,5755,Unspecified,,,,,"Dose of the compound (oral administration) showing antiinflammatory effect on rat paw edema model (reversed passive Arthus reaction-induced paw edema, RPAR)",Other,1495017.0,
345,224993,3,3,,103189031,5755,Unspecified,,,,,Oral dose required for antiinflammatory effect on zymosan induced rat paw edema.,Other,1495017.0,
346,225319,8,5,,103189031,5755,Active,126885.0,4306.0,0.037000000000000005,Ki,Binding affinity for mineralocorticoid receptor,Confirmatory,11520196.0,
347,226107,8,5,,103189031,5755,Unspecified,90110048.0,5241.0,5.0,Ki,Binding affinity for progesterone receptor,Confirmatory,11520196.0,
348,227270,8,1,,103189031,5755,Unspecified,,,,,The compound was tested for PGE-2 generation on CMC-LPS air-pouch model at 10 mg/kg by oral administration,Other,1469696.0,
349,227271,8,1,,103189031,5755,Unspecified,,,,,The compound was tested for PGE-2 generation on CMC-LPS air-pouch model at 2.5 mg/kg by oral administration,Other,1469696.0,
350,227700,3,3,,103189031,5755,Unspecified,,,,,Anticonvulsant activity,Other,12873507.0,
351,240069,5,6,,103189031,5755,Active,121069.0,2908.0,0.0045,EC50,GR-mediated transrepression of IL-6 in human A549 lung carcinoma cells,Confirmatory,15808489.0,
352,240099,8,5,,103189031,5755,Active,121073.0,14815.0,0.0034,EC50,Inhibition of mouse glutamine synthetase by GR-mediated transactivation in C2C12 cells,Confirmatory,15808489.0,
353,240130,8,5,,103189031,5755,Active,121069.0,2908.0,0.024,EC50,Inhibition of GR-mediated tyrosine amino transferase activity in human HepG2 cells,Confirmatory,15808489.0,
354,240161,8,5,,103189031,5755,Active,121073.0,14815.0,0.0057,EC50,GR-mediated transrepression of IL-6 in peritoneal exudate cells harvested from C57BI/6 mice,Confirmatory,15808489.0,
355,242155,8,5,,103189031,5755,Active,121069.0,2908.0,0.0138,IC50,Inhibition of human glucocorticoid receptor alpha by displacement of [3H]dexamethasone,Confirmatory,15808489.0,
356,243716,3,10,,103189031,5755,Unspecified,121073.0,14815.0,,,Percent absolute inhibition of LPS-induced tumor necrosis factor alpha release in mice at 3 mg/kg dose,Other,15808489.0,
357,243854,3,10,,103189031,5755,Unspecified,121073.0,14815.0,,,Percent inhibition of LPS-induced tumor necrosis factor alpha release in mice relative to prednisolone at 3 mg/kg dose,Other,15808489.0,
358,255211,8,1,,103189031,5755,Unspecified,113832.0,24208.0,42.658,IC50,Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881),Confirmatory,16134935.0,
359,267771,9,5,,103189031,5755,Inconclusive,121069.0,2908.0,,IC50,Inhibition of fluorescent-labeled Dexamethasone binding to GR,Confirmatory,16821781.0,
360,267772,7,6,,103189031,5755,Active,121069.0,2908.0,0.00851,IC50,Agonist activity at GR assessed as NF-kappaB-mediated transrepression of secreted placental alkaline phosphatase gene in human A549 cells,Confirmatory,16821781.0,
361,267773,4,12,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at GR assessed as NF-kappaB-mediated transrepression of secreted placental alkaline phosphatase gene in human A549 cells relative to Dexamethasone,Other,16821781.0,
362,267774,7,6,,103189031,5755,Inconclusive,121069.0,2908.0,,IC50,Activity at GR assessed as ability to antagonize dexamethasone-induced MMTV luciferase reporter gene transactivation in human A549 cells,Confirmatory,16821781.0,
363,267775,7,6,,103189031,5755,Unspecified,121069.0,2908.0,,EC50,Agonist activity at GR assessed as MMTV-mediated transactivation of renilla luciferase gene in human A549 cells relative to Dexamethasone,Confirmatory,16821781.0,
364,274990,7,2,,103189031,5755,Active,,,0.015,IC50,Inhibition of tetramethylrhodamine labeled dexamethasone binding to GR by FP assay,Confirmatory,17181172.0,
365,274993,4,4,,103189031,5755,Active,,,0.0066,IC50,Inhibition of IL1-stimulated IL6 production in HFF cells,Confirmatory,17181172.0,
366,274994,3,5,,103189031,5755,Unspecified,,,,,Inhibition of IL1-stimulated IL6 production in HFF cells relative to Dexamethasone,Other,17181172.0,
367,274995,4,4,,103189031,5755,Active,,,0.019,EC50,Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay,Confirmatory,17181172.0,
368,274996,3,5,,103189031,5755,Unspecified,,,,,Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay relative to Dexamethasone,Other,17181172.0,
369,274997,4,4,,103189031,5755,Active,,,0.016,EC50,Activation of MMTV in HeLa cells measured by luciferase activity,Confirmatory,17181172.0,
370,274998,3,5,,103189031,5755,Unspecified,,,,,Activation of MMTV in HeLa cells measured by luciferase activity relative to Dexamethasone,Other,17181172.0,
371,275000,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of LPS-stimulated TNFalpha production in BALB/c mouse at 3 mg/kg, po",Other,17181172.0,
372,276834,3,3,,103189031,5755,Unspecified,,,,,Antiinflammatory activity assessed as prevention of hypotonicity-induced lysis of human RBC at 50 ug/ml,Other,16996736.0,
373,276835,3,3,,103189031,5755,Unspecified,,,,,Antiinflammatory activity assessed as prevention of hypotonicity-induced lysis of human RBC at 100 ug/ml,Other,16996736.0,
374,288184,9,1,,103189031,5755,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
375,288185,7,1,,103189031,5755,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
376,288192,3,4,,103189031,5755,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
377,296300,4,3,,103189031,5755,Active,,,0.0138,IC50,Displacement of [3H]dexamethasone from human glucocorticoid receptor alpha,Confirmatory,17467988.0,
378,296301,8,5,,103189031,5755,Active,121069.0,2908.0,0.0045,EC50,Activity at human glucocorticoid receptor in human A549 cells assessed as repression of human IL6,Confirmatory,17467988.0,
379,296302,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor in human A549 cells assessed as repression of human IL6 relative to Dexamethasone,Other,17467988.0,
380,296303,8,5,,103189031,5755,Active,121069.0,2908.0,0.024,EC50,Activity at human glucocorticoid receptor in human HepG2 cells assessed as tyrosine amino transferase activity,Confirmatory,17467988.0,
381,296304,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor in human HepG2 cells assessed as tyrosine amino transferase activity relative to Dexamethasone,Other,17467988.0,
382,296305,8,5,,103189031,5755,Active,121069.0,2908.0,0.0057,EC50,Activity at human glucocorticoid receptor in C57BI/6 mouse peritoneal exudate cells assessed as repression of mouse IL6,Confirmatory,17467988.0,
383,296306,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor in C57BI/6 mouse peritoneal exudate cells assessed as repression of mouse IL6 relative to Dexamethasone,Other,17467988.0,
384,296307,8,5,,103189031,5755,Active,121069.0,2908.0,0.0034,EC50,Activity at human glucocorticoid receptor in C2C12 cells assessed as mouse glutamine synthetase activity,Confirmatory,17467988.0,
385,296308,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor in C2C12 cells assessed as mouse glutamine synthetase activity relative to Dexamethasone,Other,17467988.0,
386,296309,3,3,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha at 3 mg/kg,Other,17467988.0,
387,296311,3,3,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha at 3 mg/kg relative to prednisolone,Other,17467988.0,
388,299612,4,6,,103189031,5755,Active,,,0.0053,EC50,Agonist activity at GR by GRE activation assay,Confirmatory,17553679.0,
389,299613,4,7,,103189031,5755,Unspecified,,,,EC50,Agonist activity at GR by GRE activation assay relative to Dexamethasone,Confirmatory,17553679.0,
390,299614,4,6,,103189031,5755,Unspecified,,,1.0,IC50,Antagonist activity at GR assessed as inhibition of dexamethasone-induced GRE activation,Confirmatory,17553679.0,
391,299615,4,6,,103189031,5755,Active,,,0.0041,IC50,Activity at GR assessed as repression of TNFalpha and IL 1-beta induced E-selectin response,Confirmatory,17553679.0,
392,299616,7,2,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from glucocorticoid receptor,Confirmatory,17553679.0,
393,304379,8,2,,103189031,5755,Inconclusive,,,,IC50,Displacement of fluorescent labeled Dexamethasone from glucocorticoid receptor,Confirmatory,18038970.0,
394,304380,7,6,,103189031,5755,Active,121069.0,2908.0,0.00851,IC50,Agonist activity at glucocorticoid receptor in human A549 cells by NF-kappaB transrepression assay,Confirmatory,18038970.0,
395,304381,7,6,,103189031,5755,Active,121069.0,2908.0,0.03162,EC50,Agonist activity at glucocorticoid receptor in human A549 cells by MMTV transactivation assay,Confirmatory,18038970.0,
396,304382,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells at 10 mM by NF-kappaB transrepression assay relative to Dexamethasone,Other,18038970.0,
397,304383,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells at 10 mM by MMTV transactivation assay relative to Dexamethasone,Other,18038970.0,
398,304384,7,6,,103189031,5755,Inconclusive,121069.0,2908.0,,IC50,Antagonist activity at glucocorticoid receptor in human A549 cells transfected with MMTV luciferase reporter gene assessed as inhibition of dexamethasone-induced activation,Confirmatory,18038970.0,
399,307449,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of DNFB-induced ear edema in mouse chronic dermatitis model at 10 mg/kg, ip after 24 hrs relative to control",Other,17434735.0,
400,311367,3,6,,103189031,5755,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
401,313952,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of pleural eosinophils infiltration into BAL fluid in rat at 10 mg/kg, po tid after 24 hrs",Other,18160288.0,
402,330359,5,3,,103189031,5755,Active,121069.0,2908.0,0.004,ED50,Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay,Confirmatory,18032610.0,
403,330360,3,10,,103189031,5755,Active,1169883.0,24413.0,,,Activity at endogenous glucocorticoid receptor in rat H42E liver cells assessed as increase in transcriptional activation of phosphoenol pyruvate carboxykinase at 0.01 uM after 24 hrs by RT-PCR,Other,18032610.0,
404,330362,3,10,,103189031,5755,Active,1169883.0,24413.0,,,Activity at endogenous glucocorticoid receptor in rat H42E liver cells assessed as increase in transcriptional activation of pyruvate dehydrogenase kinase at 0.1 uM after 24 hrs by RT-PCR,Other,18032610.0,
405,330366,3,3,,103189031,5755,Active,,,,,"Inhibition of collagen-induced arthritis in DBA/1 mouse at less than 3 mg/kg, po after 15 days",Other,18032610.0,
406,330367,3,3,,103189031,5755,Unspecified,,,,,Toxicity in Swiss-Webster mouse assessed as increase in body fat at 10 mg/kg after 28 days,Other,18032610.0,
407,330368,3,3,,103189031,5755,Unspecified,,,,,Toxicity in Swiss-Webster mouse assessed as increase in body fat at 30 mg/kg after 28 days,Other,18032610.0,
408,330370,3,3,,103189031,5755,Unspecified,,,,,Toxicity in Swiss-Webster mouse assessed as decrease in bone formation at 3 mg/kg after 28 days,Other,18032610.0,
409,330371,3,3,,103189031,5755,Unspecified,,,,,Toxicity in Swiss-Webster mouse assessed as decrease in bone formation at 10 mg/kg after 28 days,Other,18032610.0,
410,330372,3,3,,103189031,5755,Unspecified,,,,,Toxicity in Swiss-Webster mouse assessed as decrease in bone formation at 30 mg/kg after 28 days,Other,18032610.0,
411,330373,3,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay relative to control,Other,18032610.0,
412,331514,7,2,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from glucocorticoid receptor,Confirmatory,18513967.0,
413,331515,11,1,,103189031,5755,Unspecified,,,1.0,Ki,Binding affinity at progesterone receptor,Confirmatory,18513967.0,
414,331516,4,7,,103189031,5755,Unspecified,,,,,Agonist activity at glucocorticoid receptor assessed as glucose response element transcriptional transactivation by luciferase assay relative to Dexamethasone,Other,18513967.0,
415,331517,8,1,,103189031,5755,Active,,,0.0053,EC50,Agonist activity at glucocorticoid receptor assessed as glucose response element transcriptional transactivation by luciferase assay,Confirmatory,18513967.0,
416,331518,4,6,,103189031,5755,Unspecified,,,,,Antagonist activity at glucocorticoid receptor assessed as inhibition of dexamethasone-induced glucose response element transcriptional transactivation by luciferase assay relative to control,Other,18513967.0,
417,331519,8,1,,103189031,5755,Unspecified,,,0.001,IC50,Antagonist activity at glucocorticoid receptor assessed as inhibition of dexamethasone-induced glucose response element transcriptional transactivation by luciferase assay,Confirmatory,18513967.0,
418,331520,4,6,,103189031,5755,Unspecified,,,,,Activity at glucocorticoid receptor assessed as repression of TNFalpha and IL1 beta-induced E-selectin expression relative to prednislone,Other,18513967.0,
419,331521,11,1,,103189031,5755,Active,,,0.0041,IC50,Activity at glucocorticoid receptor assessed as repression of TNFalpha and IL1 beta-induced E-selectin expression,Confirmatory,18513967.0,
420,342145,6,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity against peptidoglycan polysaccharide-induced arthritis in rat reactivation model after 14 days,Other,18614366.0,
421,346025,3,3,,103189031,5755,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
422,350306,7,1,,103189031,5755,Unspecified,,,,,Apparent permeability from basolateral to apical side in human Caco-2 cells by HPLC,Other,19397323.0,
423,350307,7,1,,103189031,5755,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cells by HPLC,Other,19397323.0,
424,350311,3,3,,103189031,5755,Active,,,,,Inhibition of dextran sodium sulfate-induced ulcerative colitis in po dosed BALB/c mouse assessed as decrease in body weight loss administered twice daily for 6 days relative to control,Other,19397323.0,
425,350312,3,3,,103189031,5755,Active,,,,,Inhibition of dextran sodium sulfate-induced ulcerative colitis in po dosed BALB/c mouse assessed as decrease in disease activity index administered twice daily for 6 days relative to control,Other,19397323.0,
426,350313,3,3,,103189031,5755,Active,,,,,Inhibition of dextran sodium sulfate-induced ulcerative colitis in po dosed BALB/c mouse assessed as decrease in colon shortening administered twice daily for 6 days relative to control,Other,19397323.0,
427,350315,3,3,,103189031,5755,Unspecified,,,,,Toxicity in dextran sodium sulfate treated po dosed BALB/c mouse ulcerative colitis model assessed as reduction in thymus weight to body weight ratio administered twice daily for 6 days relative to control,Other,19397323.0,
428,351941,8,5,,103189031,5755,Active,121069.0,2908.0,0.0015,Ki,Displacement of FITC-dexamethasone from human recombinant glucocorticoid receptor alpha by fluorescence polarization assay,Confirmatory,19321341.0,
429,351942,8,5,,103189031,5755,Active,121069.0,2908.0,0.0158,EC50,Transrepression activity at GR in PMA-stimulated human A549 cells assessed as inhibition of AP1 response element-induced luciferase reporter gene activity,Confirmatory,19321341.0,
430,351943,8,5,,103189031,5755,Active,121069.0,2908.0,0.0136,EC50,Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,19321341.0,
431,351944,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at GR in PMA-stimulated human A549 cells assessed as inhibition of AP1 response element-induced luciferase reporter gene activity relative to Dexamethasone,Other,19321341.0,
432,351945,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Other,19321341.0,
433,351946,7,1,,103189031,5755,Active,,,0.0827,EC50,Agonist activity at GR ligand binding domain expressed in human NP1 cells assessed as glucocorticoid response element transactivation by GAL4 luciferase reporter gene assay,Confirmatory,19321341.0,
434,351947,4,7,,103189031,5755,Unspecified,,,,,Agonist activity at GR ligand binding domain expressed in human NP1 cells assessed as glucocorticoid response element transactivation by GAL4 luciferase reporter gene assay relative to Dexamethasone,Other,19321341.0,
435,356333,6,2,,103189031,5755,Unspecified,,,,,Antiedemic activity against DMSO-induced paw edema in sc dosed Albino rat,Other,12932140.0,
436,357244,3,4,,103189031,5755,Unspecified,,,,,Inhibition of lipopolysaccharide IL1-beta production in human PMNC at 0.3 ug/mL by ELISA,Other,12502335.0,
437,357246,3,3,,103189031,5755,Unspecified,,,,,Inhibition of lipopolysaccharide IL2 production in human PMNC at 0.3 ug/mL by ELISA,Other,12502335.0,
438,357248,3,3,,103189031,5755,Unspecified,,,,,Inhibition of lipopolysaccharide IL4 production in human PMNC at 0.3 ug/mL by ELISA,Other,12502335.0,
439,357250,3,3,,103189031,5755,Unspecified,,,,,Inhibition of lipopolysaccharide TNFalpha production in human PMNC at 0.3 ug/mL by ELISA,Other,12502335.0,
440,360026,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated TNFalpha production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
441,360027,3,5,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated IL1-beta production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
442,360028,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated IL8 production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
443,360029,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated IL2 production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
444,360030,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated IL4 production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
445,360031,3,5,,103189031,5755,Unspecified,,,,,Immunosuppressive activity in human PBMC assessed as inhibition of LPS-stimulated IFN-gamma production at 0.3 ug/mL after 18 to 24 hrs by ELISA,Other,11374948.0,
446,362581,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of granuloma formation in cotton pellet implanted Lewis rat at 1.0 mg/kg, po bid",Other,18691892.0,
447,362592,6,2,,103189031,5755,Unspecified,,,,,Inhibition of LPS-induced TNFalpha production in mouse,Other,18691892.0,
448,362593,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 1.0 mg/kg, po bid for 4 days",Other,18691892.0,
449,362594,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 2.5 mg/kg, po bid for 4 days",Other,18691892.0,
450,362595,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 6.0 mg/kg, po bid for 4 days",Other,18691892.0,
451,362599,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 1.0 mg/kg, po bid for 7 days",Other,18691892.0,
452,362600,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 2.5 mg/kg, po bid for 7 days",Other,18691892.0,
453,362601,3,3,,103189031,5755,Unspecified,,,,,"Effect on body weight change in Lewis rat with implanted cotton pellets at 6.0 mg/kg, po bid for 7 days",Other,18691892.0,
454,362605,3,4,,103189031,5755,Unspecified,,,,,"Effect on spleen weight in Lewis rat with implanted cotton pellets at 1.0 mg/kg, po bid",Other,18691892.0,
455,362606,3,4,,103189031,5755,Unspecified,,,,,"Effect on spleen weight in Lewis rat with implanted cotton pellets at 2.5 mg/kg, po bid",Other,18691892.0,
456,362607,3,4,,103189031,5755,Unspecified,,,,,"Effect on spleen weight in Lewis rat with implanted cotton pellets at 6.0 mg/kg, po bid",Other,18691892.0,
457,362611,3,3,,103189031,5755,Unspecified,,,,,"Effect on thymus weight in Lewis rat with implanted cotton pellets at 1.0 mg/kg, po bid",Other,18691892.0,
458,362612,3,3,,103189031,5755,Unspecified,,,,,"Effect on thymus weight in Lewis rat with implanted cotton pellets at 2.5 mg/kg, po bid",Other,18691892.0,
459,362613,3,3,,103189031,5755,Unspecified,,,,,"Effect on thymus weight in Lewis rat with implanted cotton pellets at 6.0 mg/kg, po bid",Other,18691892.0,
460,362617,3,3,,103189031,5755,Unspecified,,,,,"Effect on adrenal weight in Lewis rat with implanted cotton pellets at 1.0 mg/kg, po bid",Other,18691892.0,
461,362618,3,3,,103189031,5755,Unspecified,,,,,"Effect on adrenal weight in Lewis rat with implanted cotton pellets at 2.5 mg/kg, po bid",Other,18691892.0,
462,362619,3,3,,103189031,5755,Unspecified,,,,,"Effect on adrenal weight in Lewis rat with implanted cotton pellets at 6.0 mg/kg, po bid",Other,18691892.0,
463,362623,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of granuloma formation in cotton pellet implanted Lewis rat at 6.0 mg/kg, po bid",Other,18691892.0,
464,362624,3,3,,103189031,5755,Unspecified,,,,,"Inhibition of granuloma formation in cotton pellet implanted Lewis rat at 2.5 mg/kg, po bid",Other,18691892.0,
465,373867,6,3,,103189031,5755,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
466,376390,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced TNFalpha production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
467,376391,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced IL8 production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
468,376392,3,5,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced IL1-beta production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
469,376393,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced IL4 production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
470,376394,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced IL2 production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
471,376395,3,5,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human PBMC assessed as inhibition of LPS-induced IFN-gamma production at 0.3 ug/ml after 24 hrs by ELISA,Other,10579865.0,
472,377220,6,2,,103189031,5755,Active,,,25.4,IC50,Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 4 hrs by ELISA,Confirmatory,11000020.0,
473,377780,3,4,,103189031,5755,Unspecified,,,,,Inhibition of LPS-induced IL10 production in human PBMC at 0.3 mg/mL after 48 hrs by ELISA,Other,15844937.0,
474,377781,3,4,,103189031,5755,Unspecified,,,,,Inhibition of LPS-induced IL12 production in human PBMC at 0.3 mg/mL after 48 hrs by ELISA,Other,15844937.0,
475,377782,3,4,,103189031,5755,Unspecified,,,,,Inhibition of LPS-induced TNFalpha production in human PBMC at 0.3 mg/mL after 48 hrs by ELISA,Other,15844937.0,
476,379618,3,3,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human peripheral mononuclear cells assessed as inhibition of LPS-stimulated IL4 production at 0.3 ug/mL,Other,10757719.0,
477,379619,3,3,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human peripheral mononuclear cells assessed as inhibition of LPS-stimulated IL2 production at 0.3 ug/mL,Other,10757719.0,
478,379620,3,4,,103189031,5755,Unspecified,,,,,Immunosuppressive activity against human peripheral mononuclear cells assessed as inhibition of LPS-stimulated IFN-gamma production at 0.3 ug/mL,Other,10757719.0,
479,394967,6,3,,103189031,5755,Active,,,0.0059,IC50,Inhibition of IL4 and LPS-induced IgE production in BALB/c mouse spleen B cell after 6 days by ELISA,Confirmatory,19179074.0,
480,394968,6,3,,103189031,5755,Active,,,0.078,IC50,Immunosuppressive activity in rat lymphocytes assessed as inhibition of mixed-lymphocyte reaction,Confirmatory,19179074.0,
481,394969,3,3,,103189031,5755,Unspecified,,,,,Inhibition of PHA-induced BALB/c mouse T cell proliferation at 10 uM,Other,19179074.0,
482,394970,4,4,,103189031,5755,Inconclusive,,,,IC50,Cytotoxicity against human K562 cells,Confirmatory,19179074.0,
483,394971,6,3,,103189031,5755,Unspecified,,,10.0,IC50,Cytotoxicity against BALB/c mouse B cells assessed as cell viability,Confirmatory,19179074.0,
484,394974,3,5,,103189031,5755,Unspecified,,,,,Selectivity for IgE production in BALB/c mouse spleen B cells over IgM production in BALB/c mouse spleen B cells,Other,19179074.0,
485,394975,3,5,,103189031,5755,Unspecified,,,,,Selectivity for IgE production in BALB/c mouse spleen B cells over IgG2a production in BALB/c mouse spleen B cells,Other,19179074.0,
486,394976,3,5,,103189031,5755,Unspecified,,,,,Selectivity for IgE production in BALB/c mouse spleen B cells over IgG1 production in BALB/c mouse spleen B cells,Other,19179074.0,
487,404304,3,10,,103189031,5755,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
488,407366,9,5,,103189031,5755,Active,119810.0,24360.0,2.66,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
489,407369,9,5,,103189031,5755,Unspecified,119810.0,24360.0,101.0,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
490,410446,8,2,,103189031,5755,Active,,,0.01259,IC50,Displacement of fluorescent labelled Dexamethasone from glucocorticoid receptor,Confirmatory,19019676.0,
491,410447,6,2,,103189031,5755,Active,,,0.01,IC50,Inhibition of TNF-induced NF-kappaB activation in human A549 cells after 15 hrs,Confirmatory,19019676.0,
492,410448,4,5,,103189031,5755,Unspecified,,,,,Inhibition of TNF-induced NFkappaB activation in human A549 cells after 15 hrs relative to Dexamethasone,Other,19019676.0,
493,410449,7,6,,103189031,5755,Active,121069.0,2908.0,0.05012,EC50,Agonist activity at human glucocorticoid receptor in human A549 cells assessed as transcriptional activity by MMTV luciferase reporter gene assay,Confirmatory,19019676.0,
494,410450,4,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at human glucocorticoid receptor in human A549 cells assessed as transcriptional activity by MMTV luciferase reporter gene assay relative to Dexamethasone,Other,19019676.0,
495,425652,7,2,,103189031,5755,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
496,425653,7,2,,103189031,5755,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
497,426622,3,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 1 hr after elicitation by immediate type reaction assay",Other,19362477.0,
498,426624,3,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 24 hrs after elicitation by late type reaction assay",Other,19362477.0,
499,434955,1,2,,50085972,5755,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
500,434959,1,1,,85788424,5755,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
501,434962,1,2,,50085972,5755,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
502,434973,1,3,,50085972,5755,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
503,434989,1,1,,50085972,5755,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
504,435003,1,3,,50085972,5755,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
505,435022,2,2,,50085972,5755,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
506,435030,1,2,,50085972,5755,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
507,435030,1,2,,50085972,5755,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
508,440586,6,2,,103189031,5755,Unspecified,,,,,Acute toxicity in rat,Other,19682771.0,
509,440597,3,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as protection against carrageenan-induced paw edema at 25 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs",Other,19682771.0,
510,440598,3,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as protection against carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs",Other,19682771.0,
511,440599,3,4,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of increase in plasma PGE2 level at 25 mg/kg, po by EIA",Other,19682771.0,
512,440600,4,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of increase in plasma PGE2 level at 50 mg/kg, po by EIA",Other,19682771.0,
513,444050,7,1,,103189031,5755,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
514,444051,6,2,,103189031,5755,Unspecified,,,,,Total clearance in human,Other,20070106.0,
515,444052,6,2,,103189031,5755,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
516,444053,6,2,,103189031,5755,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
517,444054,6,1,,103189031,5755,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
518,444055,3,3,,103189031,5755,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
519,444056,3,3,,103189031,5755,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
520,444057,3,3,,103189031,5755,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
521,444058,6,2,,103189031,5755,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
522,449728,1,2,,50085972,5755,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
523,449762,1,2,,50085972,5755,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
524,449763,1,3,,50085972,5755,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
525,463079,1,2,,50085972,5755,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
526,463082,1,1,,50085972,5755,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
527,463104,1,2,,50085972,5755,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
528,463111,1,1,,50085972,5755,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
529,463141,1,2,,50085972,5755,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
530,463165,1,1,,50085972,5755,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
531,463190,1,2,,50085972,5755,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
532,463195,1,2,,50085972,5755,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
533,463210,1,2,,50085972,5755,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
534,463212,1,1,,50085972,5755,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
535,463254,1,1,,50085972,5755,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
536,467612,3,6,,103189031,5755,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
537,467613,5,3,,103189031,5755,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
538,473409,7,5,,103189031,5755,Unspecified,121069.0,2908.0,,Ki,Displacement of [3H]DEX from human glucocorticoid receptor,Confirmatory,20334371.0,
539,476929,3,3,,103189031,5755,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
540,480395,7,5,,103189031,5755,Active,121069.0,2908.0,0.006999999999999999,IC50,Binding affinity to human glucocorticoid receptor by fluorescence polarization competitive binding assay,Confirmatory,20427184.0,
541,480396,4,6,,103189031,5755,Active,121069.0,2908.0,0.003,EC50,Agonist activity at glucocorticoid receptor in human fibroblast assessed as inhibition of IL-1-beta-induced IL6 production treated 1 hr before IL1-beta challenge measured after 24 hrs by transrepression assay,Confirmatory,20427184.0,
542,480397,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human fibroblast assessed as inhibition of IL-1-beta-induced IL6 production treated 1 hr before IL1-beta challenge measured after 24 hrs by transrepression assay relative to Dexamethasone,Other,20427184.0,
543,480398,4,6,,103189031,5755,Active,121069.0,2908.0,0.055,EC50,Agonist activity at glucocorticoid receptor in human MDA-kb2 cells transfected with MMTV-LUC assessed as induction of MMTV-LTR/promoter linked LUC gene by luciferase transactivation assay,Confirmatory,20427184.0,
544,480399,3,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human MDA-kb2 cells transfected with MMTV-LUC assessed as induction of MMTV-LTR/promoter linked LUC gene at 3.3 uM by luciferase transactivation assay relative to Dexamethasone,Other,20427184.0,
545,481237,6,2,,103189031,5755,Unspecified,,,,,Antiarthritic activity in po dosed BALB/c mouse collagen antibody induced arthritis model assessed as increase of arthritis score administered qd for 2 days after collagen antibody challenge measured after 2 days,Other,20399648.0,
546,481238,3,3,,103189031,5755,Unspecified,,,,,Toxicity in po dosed BALB/c mouse collagen antibody induced arthritis model assessed as tolerated dose,Other,20399648.0,
547,481239,3,3,,103189031,5755,Unspecified,,,,,Ratio of ED50 for BALB/c mouse collagen antibody induced arthritis model to tolerated dose for BALB/c mouse collagen antibody induced arthritis model,Other,20399648.0,
548,485270,1,1,,50085972,5755,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
549,485272,1,1,,50085972,5755,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
550,485273,2,1,,50085972,5755,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
551,485275,1,3,,50085972,5755,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
552,485281,1,1,,50085972,5755,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
553,485294,1,1,,50085972,5755,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
554,485297,1,1,,50085972,5755,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
555,485298,1,1,,50085972,5755,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
556,485313,1,2,,50085972,5755,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
557,485314,1,1,,50085972,5755,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
558,485317,1,2,,50085972,5755,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
559,485341,1,1,,50085972,5755,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
560,485344,1,1,,50085972,5755,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
561,485346,1,1,,50085972,5755,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
562,485346,1,1,,50085972,5755,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
563,485347,1,2,,50085972,5755,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
564,485349,1,1,,50085972,5755,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
565,485350,1,2,,92125114,5755,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
566,485353,2,1,,50085972,5755,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
567,485358,1,1,,50085972,5755,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
568,485364,1,1,,50085972,5755,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
569,485367,1,2,,50085972,5755,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
570,488837,1,1,,50085972,5755,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
571,488839,1,1,,56463372,5755,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
572,488839,1,1,,56463372,5755,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
573,488847,1,3,,50085972,5755,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
574,488862,1,1,,56463372,5755,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
575,488890,1,2,,50085972,5755,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
576,488895,1,2,,56463372,5755,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
577,488896,1,1,,56463372,5755,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
578,488899,1,1,,56463372,5755,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
579,488922,1,2,,50085972,5755,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
580,488965,1,2,,56463372,5755,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
581,488966,1,1,,56463372,5755,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
582,488975,1,2,,50085972,5755,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
583,488977,1,2,,50085972,5755,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
584,489030,2,1,,50085972,5755,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
585,489031,2,1,,50085972,5755,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
586,492947,1,1,,50085972,5755,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
587,492953,1,1,,56463372,5755,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
588,492956,1,1,,56463372,5755,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
589,492967,1,2,,92125114,5755,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
590,492972,1,1,,56463372,5755,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
591,493005,1,1,,50085972,5755,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
592,493008,1,1,,56463372,5755,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
593,493008,1,1,,56463372,5755,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
594,493008,1,1,,56463372,5755,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
595,493008,1,1,,56463372,5755,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
596,493011,1,1,,50085972,5755,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
597,493012,1,1,,50085972,5755,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
598,493014,1,1,,50085972,5755,Inconclusive,,,1.2589,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
599,493033,1,2,,92125114,5755,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
600,493036,1,2,,50085972,5755,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
601,493056,1,1,,50085972,5755,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
602,493083,1,1,,50085972,5755,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Activity_Set3,Confirmatory,,
603,493084,1,1,,50085972,5755,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
604,493085,1,1,,50085972,5755,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Internal-Standard_Set3,Confirmatory,,
605,493087,1,1,,56463372,5755,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
606,493091,1,1,,50085972,5755,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
607,493098,1,1,,50085972,5755,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
608,493131,1,1,,56463372,5755,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
609,493140,1,1,,103913923,5755,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
610,493160,1,1,,50085972,5755,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
611,493187,1,2,,50085972,5755,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
612,493244,1,1,,56463372,5755,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
613,493244,1,1,,56463372,5755,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
614,493244,1,1,,56463372,5755,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
615,493244,1,1,,56463372,5755,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
616,504326,1,2,,56463372,5755,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
617,504326,1,2,,56463372,5755,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
618,504327,1,1,,50085972,5755,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
619,504329,1,1,,56463372,5755,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
620,504333,1,1,,50085972,5755,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
621,504339,1,1,,50085972,5755,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
622,504357,1,1,,56463372,5755,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
623,504357,1,1,,56463372,5755,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
624,504406,1,1,,50085972,5755,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
625,504408,2,1,,50085972,5755,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
626,504411,1,1,,56463372,5755,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
627,504414,1,1,,56463372,5755,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
628,504414,1,1,,56463372,5755,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
629,504423,1,1,,56463372,5755,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
630,504441,1,1,,56463372,5755,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
631,504444,1,1,,50085972,5755,Active,224028257.0,4780.0,0.057999999999999996,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
632,504454,1,3,,56463372,5755,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
633,504462,1,1,,50085972,5755,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
634,504466,1,1,,50085972,5755,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
635,504467,1,1,,50085972,5755,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
636,504490,1,2,,56463372,5755,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
637,504523,1,1,,56463372,5755,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
638,504523,1,1,,56463372,5755,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
639,504558,1,1,,56463372,5755,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
640,504577,2,2,,56463372,5755,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
641,504582,2,1,,56463372,5755,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
642,504621,1,1,,56463372,5755,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
643,504634,1,1,,56463372,5755,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
644,504648,1,1,,50085972,5755,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
645,504651,1,1,,50085972,5755,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
646,504652,1,1,,50085972,5755,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
647,504660,1,1,,50085972,5755,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
648,504690,1,3,,50085972,5755,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
649,504692,2,2,,56463372,5755,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
650,504700,1,1,,56463372,5755,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
651,504700,1,1,,56463372,5755,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
652,504706,1,1,,50085972,5755,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
653,504707,1,1,,56463372,5755,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
654,504707,1,1,,56463372,5755,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
655,504720,1,1,,50085972,5755,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
656,504734,1,1,,56463372,5755,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
657,504766,2,1,,56463372,5755,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
658,504775,1,1,,56463372,5755,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
659,504803,1,1,,56463372,5755,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
660,504810,1,2,,50085972,5755,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
661,504812,1,2,,50085972,5755,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
662,504832,1,1,,50085972,5755,Inactive,,,14.7157,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
663,504834,1,1,,50085972,5755,Inactive,,,0.4654,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
664,504842,1,1,,50085972,5755,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
665,504845,1,1,,50085972,5755,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
666,504847,1,1,,50085972,5755,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
667,504884,1,2,,56463372,5755,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
668,504891,1,1,,50085972,5755,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
669,504894,1,1,,50085972,5755,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
670,504937,1,2,,50085972,5755,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
671,515514,5,1,,103189031,5755,Active,,,0.015,IC50,Binding affinity to glucocorticoid receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled Dexamethasone by fluorescence polarization microplate assay,Confirmatory,20735001.0,
672,515515,5,1,,103189031,5755,Unspecified,,,2.0,IC50,Binding affinity to progesterone receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled RU-486 by fluorescence polarization microplate assay,Confirmatory,20735001.0,
673,515516,5,1,,103189031,5755,Active,,,0.044000000000000004,IC50,Binding affinity to mineralocorticoid receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled Dexamethasone by fluorescence polarization microplate assay,Confirmatory,20735001.0,
674,515517,6,5,,103189031,5755,Active,121069.0,2908.0,0.0066,IC50,Transrepression activity at glucocorticoid receptor in HFF assessed as inhibition of IL-1-induced IL-6 production after 18 to 24 hrs by ELISA,Confirmatory,20735001.0,
675,515518,2,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in HFF assessed as inhibition of IL-1-induced IL-6 production after 18 to 24 hrs by ELISA relative to Dexamethasone,Other,20735001.0,
676,515536,2,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory effect in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as inhibition of disease progression at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
677,515537,5,2,,103189031,5755,Unspecified,,,,,Antiinflammatory effect in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as inhibition of disease progression administered as po qd for 5 weeks,Other,20735001.0,
678,515538,2,3,,103189031,5755,Unspecified,,,,,"Toxicity in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as increase of body fat content at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
679,515539,2,4,,103189031,5755,Unspecified,,,,,"Toxicity in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as increase of serum insulin level at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
680,515540,2,3,,103189031,5755,Unspecified,,,,,"Toxicity in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as increase of triglyceride level at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
681,515541,2,3,,103189031,5755,Unspecified,,,,,"Toxicity in collagen and Freund's complete adjuvant-induced B10.RIII mouse arthritis model assessed as increase of free fatty acids level at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
682,515542,2,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as increase of body fat content at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
683,515543,2,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as increase of triglyceride level at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
684,515544,2,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as increase of serum insulin level at 30 mg/kg, po qd for 5 weeks",Other,20735001.0,
685,538370,1,4,,103189031,5755,Inactive,,,,,Cytotoxicity against human LNCAP cells at 100 pM to 1 uM,Other,20936874.0,
686,540209,4,3,,103189031,5755,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
687,540210,4,3,,103189031,5755,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
688,540211,2,5,,103189031,5755,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
689,540212,4,3,,103189031,5755,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
690,540213,4,3,,103189031,5755,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
691,540253,1,1,,50085972,5755,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
692,540253,1,1,,50085972,5755,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
693,540253,1,1,,50085972,5755,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
694,540263,1,1,,50085972,5755,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
695,540263,1,1,,50085972,5755,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
696,540267,1,1,,50085972,5755,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
697,540275,1,1,,50085972,5755,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
698,540277,1,1,,50085972,5755,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
699,540295,1,1,,56463372,5755,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
700,540299,1,2,,92125114,5755,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
701,540303,1,1,,50085972,5755,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
702,540303,1,1,,50085972,5755,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
703,540303,1,1,,50085972,5755,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
704,540308,1,1,,56463372,5755,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
705,540317,1,1,,50085972,5755,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
706,540336,1,1,,56463372,5755,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
707,540336,1,1,,56463372,5755,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
708,540364,1,2,,56463372,5755,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
709,552717,5,1,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from glucocorticoid receptor expressed in baculovirus,Confirmatory,21115247.0,
710,552718,5,2,,103189031,5755,Inactive,,,,Ki,Binding affinity to progesterone receptor,Confirmatory,21115247.0,
711,552719,2,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with GRE assessed as transactivation activity by luciferase reporter gene assay relative to Dexamethasone,Other,21115247.0,
712,552720,3,6,,103189031,5755,Active,121069.0,2908.0,0.0053,EC50,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with GRE assessed as transactivation activity by luciferase reporter gene assay,Confirmatory,21115247.0,
713,552721,2,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in TNFalpha/IL1beta-stimulated human HepG2 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Other,21115247.0,
714,552806,6,5,,103189031,5755,Active,121069.0,2908.0,0.0041,IC50,Transrepression activity at glucocorticoid receptor in TNFalpha/IL1beta-stimulated human HepG2 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,21115247.0,
715,552807,2,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in IL-1beta-stimulated human HepG2 cells assessed as inhibition of AP1 response element-induced IL-6 production by ELISA relative to Dexamethasone,Other,21115247.0,
716,552808,6,5,,103189031,5755,Active,121069.0,2908.0,0.023,IC50,Transrepression activity at glucocorticoid receptor in IL-1beta-stimulated human HepG2 cells assessed as inhibition of AP1 response element-induced IL-6 production by ELISA,Confirmatory,21115247.0,
717,578372,2,7,,103189031,5755,Unspecified,,,,,Agonist activity at GR expressed in rat H4IIEC3 cells assessed as induction of PEPCK transactivation by luciferase reporter gene assay relative to Dexamethasone,Other,21349714.0,
718,578373,5,2,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from GR,Confirmatory,21349714.0,
719,578374,6,1,,103189031,5755,Active,,,0.0053,EC50,Agonist activity at GR expressed in african green monkey CV1 cells transfected with luciferase gene linked to MMTV promoter assessed as induction of luciferase transactivation activity,Confirmatory,21349714.0,
720,578375,2,7,,103189031,5755,Unspecified,,,,,Agonist activity at GR expressed in african green monkey CV1 cells transfected with luciferase gene linked to MMTV promoter assessed as induction of luciferase transactivation activity relative to Dexamethasone,Other,21349714.0,
721,578376,2,6,,103189031,5755,Active,,,0.026000000000000002,EC50,Agonist activity at GR expressed in rat H4IIEC3 cells assessed as induction of PEPCK transactivation by luciferase reporter gene assay,Confirmatory,21349714.0,
722,578377,9,1,,103189031,5755,Active,,,0.0041,IC50,Transrepression activity at GR expressed in IL-1beta- and TNFalpha-stimulated HepG2 cells assessed as inhibition of NFKB- or AP-1 mediated E-selectin transcription by luciferase reporter gene assay,Confirmatory,21349714.0,
723,578378,2,7,,103189031,5755,Unspecified,,,,,Transrepression activity at GR expressed in IL-1beta- and TNFalpha-stimulated HepG2 cells assessed as inhibition of NFKB- or AP-1 mediated E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Other,21349714.0,
724,578481,9,1,,103189031,5755,Active,,,0.023,IC50,Transrepression activity at GR expressed in NHDF cells assessed as IL-1beta-mediated IL-6 transcription by ELISA,Confirmatory,21349714.0,
725,578482,2,7,,103189031,5755,Unspecified,,,,,Transrepression activity at GR expressed in NHDF cells assessed as IL-1beta-mediated IL-6 transcription by ELISA relative to Dexamethasone,Other,21349714.0,
726,579568,5,2,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from GR,Confirmatory,21316964.0,
727,579569,6,1,,103189031,5755,Active,,,0.0053,EC50,Agonist activity at GR expressed in african green monkey CV1 cells transfected with luciferase gene linked to MMTV promoter assessed as induction of luciferase transactivation activity relative to Dexamethasone,Confirmatory,21316964.0,
728,579570,2,6,,103189031,5755,Unspecified,,,,,Agonist activity at GR expressed in african green monkey CV1 cells transfected with luciferase gene linked to MMTV promoter assessed as induction of luciferase transactivation activity,Other,21316964.0,
729,579571,6,1,,103189031,5755,Active,,,0.0041,IC50,Agonist activity at GR expressed in IL-1beta- and TNFalpha-stimulated HepG2 cells assessed as inhibition of NFKB- or AP-1 mediated E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Confirmatory,21316964.0,
730,579572,2,6,,103189031,5755,Unspecified,,,,,Agonist activity at GR expressed in IL-1beta- and TNFalpha-stimulated HepG2 cells assessed as inhibition of NFKB- or AP-1 mediated E-selectin transcription by luciferase reporter gene assay,Other,21316964.0,
731,579573,7,2,,103189031,5755,Active,121069.0,2908.0,0.023,IC50,Agonist activity at human GR expressed in NHDF cells assessed as inhibition of IL-6 production by ELISA relative to Dexamethasone,Confirmatory,21316964.0,
732,579574,2,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at human GR expressed in NHDF cells assessed as inhibition of IL-6 production by ELISA,Other,21316964.0,
733,588211,2,3,,103189031,5755,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
734,588212,2,3,,103189031,5755,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
735,588213,2,3,,103189031,5755,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
736,588334,1,1,,56463372,5755,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
737,588335,1,1,,56463372,5755,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
738,588342,1,1,,50085972,5755,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
739,588352,1,2,,56463372,5755,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
740,588354,1,1,,56463372,5755,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
741,588358,1,2,,56463372,5755,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
742,588391,1,1,,56463372,5755,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
743,588405,1,1,,56463372,5755,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
744,588413,1,2,,50085972,5755,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
745,588436,1,1,,56463372,5755,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
746,588453,1,1,,50085972,5755,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
747,588456,1,1,,50085972,5755,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
748,588458,1,1,,56463372,5755,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
749,588473,1,1,,50085972,5755,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
750,588473,1,1,,50085972,5755,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
751,588475,1,2,,50085972,5755,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
752,588475,1,2,,50085972,5755,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
753,588478,1,2,,124799622,5755,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
754,588489,1,1,,56463372,5755,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
755,588492,1,1,,56463372,5755,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
756,588493,1,2,,56463372,5755,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
757,588497,1,2,,56463372,5755,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
758,588497,1,2,,56463372,5755,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
759,588497,1,2,,56463372,5755,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
760,588499,1,3,,56463372,5755,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
761,588499,1,3,,56463372,5755,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
762,588499,1,3,,56463372,5755,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
763,588501,1,2,,56463372,5755,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
764,588501,1,2,,56463372,5755,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
765,588501,1,2,,56463372,5755,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
766,588511,1,2,,50085972,5755,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
767,588519,1,2,,92125114,5755,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
768,588549,1,1,,56463372,5755,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
769,588579,1,1,,50085972,5755,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
770,588590,1,1,,50085972,5755,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
771,588591,1,1,,50085972,5755,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
772,588621,1,1,,56463372,5755,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
773,588627,1,1,,50085972,5755,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
774,588664,1,2,,56463372,5755,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
775,588664,1,2,,56463372,5755,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
776,588674,1,2,,56463372,5755,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
777,588675,1,1,,50085972,5755,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
778,588676,1,1,,50085972,5755,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
779,588689,1,1,,56463372,5755,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
780,588692,2,1,,56463372,5755,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
781,588726,1,2,,56463372,5755,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
782,588727,1,1,,56463372,5755,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
783,588795,1,1,,50085972,5755,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
784,588814,1,3,,56463372,5755,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
785,588819,1,4,,56463372,5755,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
786,588827,1,1,,50085972,5755,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_Dose_CherryPick_Activity_Set4,Confirmatory,,
787,588834,2,1,,144204880,5755,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
788,588847,1,1,,50085972,5755,Inactive,2190535.0,,52.0,AC50_uM,Luciferase Inhibition Counter Screen Measured in Biochemical System Using Plate Reader - 2038-06_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
789,588850,1,1,,56463372,5755,Active,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
790,588852,1,3,,56463372,5755,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
791,588855,1,1,,50085972,5755,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
792,588856,1,1,,50085972,5755,Inactive,,,0.1,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
793,589652,4,1,,103189031,5755,Active,,,0.0053,Ki,Displacement of radiolabeled Dexamethasone from glucocorticoid receptor expressed in baculovirus,Confirmatory,21324689.0,
794,589653,5,5,,103189031,5755,Active,121069.0,2908.0,0.0041,IC50,Transrepression activity at glucocorticoid receptor in human HepG2 cells assessed as inhibition of TNFalpha/IL1beta-stimulated NFkappaB-dependent E-selectin repression by luciferase reporter gene assay,Confirmatory,21324689.0,
795,589654,1,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in human HepG2 cells assessed as inhibition of TNFalpha/IL1beta-stimulated NFkappaB-dependent E-selectin repression by luciferase reporter gene assay relative to Dexamethasone,Other,21324689.0,
796,589655,5,5,,103189031,5755,Active,121069.0,2908.0,0.023,IC50,Transrepression activity at glucocorticoid receptor in human NHDF cells assessed as inhibition of IL-1beta-stimulated AP1 dependent IL-6 repression by ELISA,Confirmatory,21324689.0,
797,589656,1,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in human NHDF cells assessed as inhibition of IL-1beta-stimulated AP1 dependent IL-6 repression by ELISA relative to Dexamethasone,Other,21324689.0,
798,589660,2,6,,103189031,5755,Active,121069.0,2908.0,0.0053,EC50,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with GRE assessed as GRE activation by luciferase reporter gene assay,Confirmatory,21324689.0,
799,589744,1,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with GRE assessed as GRE activation by luciferase reporter gene assay relative to Dexamethasone,Other,21324689.0,
800,589745,2,6,,103189031,5755,Active,121069.0,2908.0,0.026000000000000002,EC50,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with PEPCK assessed as GRE activation by luciferase reporter gene assay,Confirmatory,21324689.0,
801,589746,1,11,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human HepG2 cells co-transfected with PEPCK assessed as GRE activation by luciferase reporter gene assay relative to Dexamethasone,Other,21324689.0,
802,599697,1,3,,103189031,5755,Active,,,,,"Analgesic effect in po dosed Lewis rat peptidoglycan-polysaccharide-induced reactivation arthritis model assessed as increase in weight bearing on injected paw at 2 mg/kg, po bid for 3 days",Other,19772287.0,
803,602123,1,1,,56463372,5755,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
804,602141,1,1,,56463372,5755,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
805,602162,1,1,,56463372,5755,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
806,602163,1,1,,56463372,5755,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
807,602179,1,2,,50085972,5755,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
808,602229,1,1,,56463372,5755,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
809,602233,1,1,,50085972,5755,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
810,602244,1,2,,56463372,5755,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
811,602247,1,2,,56463372,5755,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
812,602248,1,2,,56463372,5755,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
813,602250,1,2,,56463372,5755,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
814,602252,1,1,,56463372,5755,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
815,602252,1,1,,56463372,5755,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
816,602261,1,1,,56463372,5755,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
817,602266,1,1,,50085972,5755,Inactive,62740231.0,15499.0,,AC50_uM,Quantitative-PCR analysis for transcription inhibition of HSF-1 target gene Hsp90aa Measured in Cell-Based System Using RT-PCR - 2038-08_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
818,602274,1,2,,56463372,5755,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
819,602281,1,1,,56463372,5755,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
820,602281,1,1,,56463372,5755,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
821,602310,1,2,,50085972,5755,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
822,602313,1,1,,50085972,5755,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
823,602314,1,2,,92125114,5755,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
824,602329,1,1,,56463372,5755,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
825,602332,1,1,,50085972,5755,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
826,602340,1,2,,56463372,5755,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
827,602342,2,1,,56463372,5755,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
828,602346,1,1,,56463372,5755,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
829,602363,1,1,,56463372,5755,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
830,602393,1,1,,56463372,5755,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
831,602396,1,2,,56463372,5755,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
832,602399,1,2,,56463372,5755,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
833,602405,1,1,,56463372,5755,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
834,602410,1,1,,56463372,5755,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
835,602429,1,1,,56463372,5755,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
836,602438,1,1,,56463372,5755,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
837,602440,1,1,,56463372,5755,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
838,602449,1,2,,56463372,5755,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
839,602481,1,1,,56463372,5755,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
840,604792,6,2,,103189031,5755,Unspecified,,,5.0,Ki,Binding affinity to ERalpha by fluorescence polarization assay,Confirmatory,21073190.0,
841,604793,4,2,,103189031,5755,Unspecified,,,6.0,Ki,Binding affinity to progesterone receptor by fluorescence polarization assay,Confirmatory,21073190.0,
842,604795,4,2,,103189031,5755,Active,,,0.0015,Ki,Displacement of GS-red from GRapha by fluorescence polarization assay,Confirmatory,21073190.0,
843,604797,5,5,,103189031,5755,Active,121069.0,2908.0,0.0158,EC50,Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay,Confirmatory,21073190.0,
844,604798,1,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay relative to Dexamethasone,Other,21073190.0,
845,604799,5,5,,103189031,5755,Active,121069.0,2908.0,0.0827,EC50,Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay,Confirmatory,21073190.0,
846,604800,5,5,,103189031,5755,Active,121069.0,2908.0,0.0136,EC50,Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,21073190.0,
847,604852,1,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Other,21073190.0,
848,604853,1,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay relative to Dexamethasone,Other,21073190.0,
849,604854,5,5,,103189031,5755,Active,121069.0,2908.0,0.0574,EC50,Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs,Confirmatory,21073190.0,
850,604855,1,10,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs relative to Dexamethasone,Other,21073190.0,
851,604856,4,6,,103189031,5755,Active,126885.0,4306.0,0.002,EC50,Agonist activity at mineralocorticoid receptor in human A549 cells,Confirmatory,21073190.0,
852,604860,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema Sprague-Dawley rat model assessed as inhibition of hind paw swelling at 30 mg/kg, po measured after 5 hrs post carrageenan challenge",Other,21073190.0,
853,604861,4,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in po dosed carrageenan-induced paw edema Sprague-Dawley rat model assessed as inhibition of hind paw swelling after 5 hrs post carrageenan challenge,Other,21073190.0,
854,604862,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in carrageenan-induced paw edema Sprague-Dawley rat model assessed as increase in blood glucose level at 30 mg/kg, po measured after 5 hrs post carrageenan challenge by glucometer",Other,21073190.0,
855,604866,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as induction of TAT activity in liver homogenates at 30 mg/kg, po after 6 hrs",Other,21073190.0,
856,604871,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as increase in serum glucose level at 30 mg/kg, po after 6 hrs",Other,21073190.0,
857,604945,1,9,,103189031,5755,Unspecified,126885.0,4306.0,,,Agonist activity at mineralocorticoid receptor in human A549 cells relative to control,Other,21073190.0,
858,623870,1,1,,56463372,5755,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
859,623870,1,1,,56463372,5755,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
860,623877,1,1,,56463372,5755,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
861,623901,1,1,,56463372,5755,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
862,624037,1,3,,56463372,5755,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
863,624038,1,3,,56463372,5755,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
864,624040,1,3,,56463372,5755,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
865,624101,1,2,,85788424,5755,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
866,624125,1,4,,56463372,5755,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
867,624126,1,3,,56463372,5755,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
868,624127,1,2,,56463372,5755,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
869,624137,1,1,,85788424,5755,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
870,624151,1,1,,85788424,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
871,624156,1,1,,85788424,5755,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
872,624168,1,1,,56463372,5755,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
873,624169,1,1,,56463372,5755,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
874,624170,1,1,,50085972,5755,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
875,624171,1,1,,50085972,5755,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
876,624172,1,1,,50085972,5755,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
877,624173,1,3,,50085972,5755,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
878,624178,1,1,,50085972,5755,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
879,624202,1,1,,50085972,5755,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
880,624204,1,2,,56463372,5755,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
881,624246,1,1,,50085972,5755,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
882,624256,1,2,,56463372,5755,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
883,624260,1,1,,85788424,5755,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
884,624263,1,1,,50085972,5755,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
885,624263,1,1,,50085972,5755,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
886,624267,1,2,,56463372,5755,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
887,624267,1,2,,56463372,5755,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
888,624268,1,3,,56463372,5755,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
889,624288,1,1,,50085972,5755,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
890,624296,1,1,,50085972,5755,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
891,624297,1,1,,50085972,5755,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
892,624304,1,2,,56463372,5755,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
893,624330,1,2,,56463372,5755,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
894,624349,1,2,,92125114,5755,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
895,624349,1,2,,92309181,5755,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
896,624349,1,2,,121362434,5755,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
897,624349,1,2,,121362785,5755,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
898,624352,1,1,,56463372,5755,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
899,624354,1,1,,56463372,5755,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
900,624377,1,1,,56463372,5755,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
901,624414,1,1,,50085972,5755,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
902,624415,1,2,,50085972,5755,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
903,624416,1,1,,56463372,5755,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
904,624417,1,1,,50085972,5755,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
905,624418,1,1,,50085972,5755,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
906,624463,1,1,,50085972,5755,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
907,624464,1,1,,50085972,5755,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
908,624465,1,1,,50085972,5755,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
909,624466,1,3,,56463372,5755,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
910,624467,1,1,,56463372,5755,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
911,624483,1,1,,56463372,5755,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
912,625144,5,5,,103189031,5755,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
913,625145,4,7,,103189031,5755,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
914,625146,5,5,,103189031,5755,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
915,625147,4,7,,103189031,5755,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
916,625148,4,7,,103189031,5755,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
917,625149,4,7,,103189031,5755,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
918,625150,5,5,,103189031,5755,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
919,625151,4,7,,103189031,5755,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
920,625152,4,7,,103189031,5755,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
921,625153,4,7,,103189031,5755,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
922,625154,4,7,,103189031,5755,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
923,625155,4,7,,103189031,5755,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
924,625156,1,9,,103189031,5755,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
925,625157,6,2,,103189031,5755,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
926,625158,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
927,625159,5,5,,103189031,5755,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
928,625160,1,9,,103189031,5755,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
929,625161,4,7,,103189031,5755,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
930,625162,4,7,,103189031,5755,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
931,625163,4,7,,103189031,5755,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
932,625164,1,6,,103189031,5755,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
933,625165,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
934,625166,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
935,625167,5,5,,103189031,5755,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
936,625168,4,7,,103189031,5755,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
937,625169,1,6,,103189031,5755,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
938,625170,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
939,625171,4,7,,103189031,5755,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
940,625172,4,7,,103189031,5755,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
941,625173,5,5,,103189031,5755,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
942,625174,5,5,,103189031,5755,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
943,625175,5,5,,103189031,5755,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
944,625176,1,9,,103189031,5755,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
945,625177,5,5,,103189031,5755,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
946,625178,5,5,,103189031,5755,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
947,625179,1,9,,103189031,5755,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
948,625180,5,5,,103189031,5755,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
949,625181,5,5,,103189031,5755,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
950,625182,5,5,,103189031,5755,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
951,625183,5,5,,103189031,5755,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
952,625184,5,5,,103189031,5755,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
953,625185,5,5,,103189031,5755,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
954,625186,5,5,,103189031,5755,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
955,625187,5,5,,103189031,5755,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
956,625188,1,9,,103189031,5755,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
957,625189,1,7,,103189031,5755,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
958,625190,4,5,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
959,625191,4,7,,103189031,5755,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
960,625192,4,7,,103189031,5755,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
961,625193,5,5,,103189031,5755,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
962,625194,4,7,,103189031,5755,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
963,625195,4,7,,103189031,5755,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
964,625196,5,6,,103189031,5755,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
965,625197,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
966,625198,4,7,,103189031,5755,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
967,625199,4,7,,103189031,5755,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
968,625200,4,7,,103189031,5755,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
969,625201,4,7,,103189031,5755,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
970,625202,4,7,,103189031,5755,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
971,625203,4,7,,103189031,5755,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
972,625204,4,7,,103189031,5755,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
973,625205,4,7,,103189031,5755,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
974,625206,4,7,,103189031,5755,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
975,625207,4,7,,103189031,5755,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
976,625208,5,5,,103189031,5755,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
977,625209,4,7,,103189031,5755,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
978,625210,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
979,625211,1,6,,103189031,5755,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
980,625212,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
981,625213,4,7,,103189031,5755,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
982,625214,1,9,,103189031,5755,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
983,625215,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
984,625216,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
985,625217,4,7,,103189031,5755,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
986,625218,4,7,,103189031,5755,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
987,625219,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
988,625220,4,7,,103189031,5755,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
989,625221,4,7,,103189031,5755,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
990,625222,4,7,,103189031,5755,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
991,625223,4,7,,103189031,5755,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
992,625224,3,4,,103189031,5755,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
993,625225,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
994,625226,4,7,,103189031,5755,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
995,625227,4,7,,103189031,5755,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
996,625228,4,7,,103189031,5755,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
997,625229,5,5,,103189031,5755,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
998,625230,1,6,,103189031,5755,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
999,625231,4,7,,103189031,5755,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1000,625232,1,9,,103189031,5755,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1001,625233,4,7,,103189031,5755,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1002,625234,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1003,625235,4,7,,103189031,5755,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1004,625236,5,5,,103189031,5755,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1005,625237,4,7,,103189031,5755,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1006,625238,4,7,,103189031,5755,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1007,625239,4,7,,103189031,5755,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1008,625240,1,9,,103189031,5755,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1009,625241,4,7,,103189031,5755,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1010,625242,4,7,,103189031,5755,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1011,625243,5,5,,103189031,5755,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1012,625244,5,5,,103189031,5755,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1013,625245,5,5,,103189031,5755,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1014,625246,1,9,,103189031,5755,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1015,625247,5,5,,103189031,5755,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1016,625248,5,5,,103189031,5755,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1017,625249,5,5,,103189031,5755,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1018,625250,5,5,,103189031,5755,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1019,625251,5,5,,103189031,5755,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1020,625252,4,7,,103189031,5755,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1021,625253,4,7,,103189031,5755,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1022,625254,4,7,,103189031,5755,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1023,625255,4,7,,103189031,5755,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1024,625256,4,7,,103189031,5755,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1025,625257,4,7,,103189031,5755,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1026,625258,4,7,,103189031,5755,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1027,625259,4,7,,103189031,5755,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1028,625260,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1029,625261,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1030,625262,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1031,625263,4,7,,103189031,5755,Active,121069.0,2908.0,0.016,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1032,625264,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1033,625265,1,6,,103189031,5755,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1034,625266,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1035,625267,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1036,625268,4,2,,103189031,5755,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1037,625268,4,2,,103189031,5755,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1038,625268,4,2,,103189031,5755,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1039,625268,4,2,,103189031,5755,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1040,625269,4,7,,103189031,5755,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1041,625270,4,7,,103189031,5755,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1042,625271,5,5,,103189031,5755,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1043,625272,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1044,625273,4,6,,103189031,5755,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1045,625274,1,6,,103189031,5755,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1046,625275,3,4,,103189031,5755,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1047,625277,1,3,,103189031,5755,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1048,625279,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1049,625280,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1050,625281,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1051,625282,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1052,625283,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1053,625284,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1054,625285,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1055,625286,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1056,625287,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1057,625288,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1058,625289,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1059,625290,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1060,625291,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1061,625292,1,3,,103189031,5755,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1062,626140,4,5,,103189031,5755,Active,121069.0,2908.0,0.015,IC50,Displacement of tetramethylrhodamine-labeled Dexamethasone from human recombinant glucocorticoid receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1063,626141,4,5,,103189031,5755,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of tetramethylrhodamine-labeled RU-486 from human recombinant progesterone receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1064,626142,4,5,,103189031,5755,Active,126885.0,4306.0,0.044000000000000004,IC50,Displacement of tetramethylrhodamine-labeled Dexamethasone from human recombinant mineralocorticoid receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1065,626143,1,9,,103189031,5755,Inactive,1018618719.0,367.0,,,Displacement of [3H]-testosterone from human recombinant androgen receptor expressed in baculovirus infected insect cells at 2000 nM,Other,21963986.0,
1066,626146,2,6,,103189031,5755,Active,121069.0,2908.0,0.006999999999999999,IC50,Agonist activity at glucocorticoid receptor in HFF assessed as inhibition of IL1-induced IL-6 production after 18 to 24 hrs,Confirmatory,21963986.0,
1067,626199,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in HFF assessed as inhibition of IL1-induced IL-6 production after 18 to 24 hrs relative to Dexamethasone,Other,21963986.0,
1068,626200,4,5,,103189031,5755,Active,121069.0,2908.0,0.019,EC50,Transactivation activity of glucocorticoid receptor in HFF assessed as induction of aromatase activity by measuring beta-estradiol activity after 18 to 24 hrs by ELISA,Confirmatory,21963986.0,
1069,626201,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity of glucocorticoid receptor in HFF assessed as induction of aromatase activity by measuring beta-estradiol activity after 18 to 24 hrs by ELISA relative to Dexamethasone,Other,21963986.0,
1070,626202,2,6,,103189031,5755,Active,121069.0,2908.0,0.016,EC50,Agonist activity at glucocorticoid receptor in human HeLa cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity,Confirmatory,21963986.0,
1071,626203,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human HeLa cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity relative to Dexamethasone,Other,21963986.0,
1072,626221,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in mouse plasma assessed as inhibition of LPS-induced TNFalpha production at 10 mg/kg, po administered 1 hr before LPS challenge measured after 1 hr",Other,21963986.0,
1073,626223,1,3,,103189031,5755,Unspecified,,,,,"Antiarthritic activity in B10.R3 mouse collagen-induced arthritis model assessed as AUC of disease progression inhibition at 30 mg/kg, po qd for 5 weeks",Other,21963986.0,
1074,626270,1,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in body weight at 3 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1075,626271,1,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in body weight at 30 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1076,626272,1,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in body fat level at 3 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1077,626273,1,3,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in body fat level at 30 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1078,626274,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum triglyceride level at 3 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1079,626275,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum triglyceride level at 30 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1080,626276,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum free fatty acids level at 3 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1081,626277,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum free fatty acids level at 30 mg/kg, po qd for 5 weeks relative to control",Other,21963986.0,
1082,626278,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum insulin level at 3 mg/kg, po qd for 5 weeks by ELISA relative to control",Other,21963986.0,
1083,626279,1,4,,103189031,5755,Unspecified,,,,,"Toxicity in B10.R3 mouse collagen-induced arthritis model assessed as change in serum insulin level at 30 mg/kg, po qd for 5 weeks by ELISA relative to control",Other,21963986.0,
1084,626280,1,3,,103189031,5755,Unspecified,,,,,"Antiarthritic activity in B10.R3 mouse collagen-induced arthritis model assessed as AUC of disease progression inhibition at 3 mg/kg, po qd for 5 weeks",Other,21963986.0,
1085,626281,1,3,,103189031,5755,Unspecified,,,,,"Antiarthritic activity in B10.R3 mouse collagen-induced arthritis model assessed as AUC of disease progression inhibition at 10 mg/kg, po qd for 5 weeks",Other,21963986.0,
1086,626799,3,2,,103189031,5755,Active,,,0.0015,Ki,Displacement of GS-red from glucocorticoid receptor by fluorescence polarization assay,Confirmatory,21899328.0,
1087,626800,3,2,,103189031,5755,Unspecified,,,6.0,Ki,Displacement of fluorescently labeled ligand from progesterone receptor by fluorescence polarization assay,Confirmatory,21899328.0,
1088,626802,5,2,,103189031,5755,Unspecified,,,5.0,Ki,Displacement of fluorescently labeled ligand from ERalpha receptor by fluorescence polarization assay,Confirmatory,21899328.0,
1089,626803,6,2,,103189031,5755,Active,126885.0,4306.0,2e-06,EC50,Agonist activity at human mineralocorticoid receptor expressed in human A549 cells by fluorescence polarization assay,Confirmatory,21899328.0,
1090,626804,4,5,,103189031,5755,Active,121069.0,2908.0,0.0161,EC50,Transrepression activity at glucocorticoid receptor alpha in phorbol myristate acetate-stimulated human A549 cells assessed as inhibition of AP1 response element by luciferase reporter gene assay,Confirmatory,21899328.0,
1091,626805,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor alpha in phorbol myristate acetate-stimulated human A549 cells assessed as inhibition of AP1 response element by luciferase reporter gene assay relative to Dexamethasone,Other,21899328.0,
1092,626806,4,5,,103189031,5755,Active,121069.0,2908.0,0.0144,EC50,Transrepression activity at glucocorticoid receptor alpha in IL-1beta-stimulated human A549 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,21899328.0,
1093,626807,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor alpha in IL-1beta-stimulated human A549 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone,Other,21899328.0,
1094,626808,4,5,,103189031,5755,Active,121069.0,2908.0,0.0739,EC50,Transactivation activity at GR-alpha in human NP1 Hela cells assessed as induction of GAL4-DBD after 20 hrs by luciferase reporter gene assay,Confirmatory,21899328.0,
1095,626809,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity at GR-alpha in human NP1 Hela cells assessed as induction of GAL4-DBD after 20 hrs by luciferase reporter gene assay relative to Dexamethasone,Other,21899328.0,
1096,626810,4,5,,103189031,5755,Active,121069.0,2908.0,0.064,EC50,Transactivation activity at glucocorticoid receptor alpha human 13D3/Huh7 cells assessed as induction of TAT activity after 4 hrs by spectrophotometry,Confirmatory,21899328.0,
1097,626811,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity at glucocorticoid receptor alpha human 13D3/Huh7 cells assessed as induction of TAT activity after 4 hrs by spectrophotometry relative to Dexamethasone,Other,21899328.0,
1098,626812,4,5,,103189031,5755,Active,121069.0,2908.0,0.021,EC50,Transactivation activity at GR-alpha in human NP1 Hela cells assessed as inhibition of GAL4-DBD after 20 hrs by luciferase reporter gene assay,Confirmatory,21899328.0,
1099,626813,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation activity at GR-alpha in human NP1 Hela cells assessed as inhibition of GAL4-DBD after 20 hrs by luciferase reporter gene assay in presence of 100 nM Dexamethasone,Other,21899328.0,
1100,626814,1,4,,103189031,5755,Unspecified,,,,,Induction of alkaline phosphatase expression in human Saos2 cells after 3 days by spectrophotometry,Other,21899328.0,
1101,626815,1,4,,103189031,5755,Active,,,0.019,EC50,Induction of glutamine synthase expression in human MG63 cells after overnight incubation by spectrophotometry,Confirmatory,21899328.0,
1102,626816,1,4,,103189031,5755,Unspecified,,,,,Induction of glutamine synthase expression in human MG63 cells after overnight incubation by spectrophotometry relative to prednisolone,Other,21899328.0,
1103,626817,1,4,,103189031,5755,Active,,,0.08900000000000001,EC50,Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after overnight incubation by ELISA,Confirmatory,21899328.0,
1104,626818,1,4,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after overnight incubation by ELISA relative to Dexamethasone,Other,21899328.0,
1105,626819,1,4,,103189031,5755,Active,,,0.124,EC50,Antiinflammatory activity in human whole blood assessed as inhibition of TNF-alpha-induced IL-8 production after overnight incubation by ELISA,Confirmatory,21899328.0,
1106,626820,1,4,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human whole blood assessed as inhibition of TNF-alpha-induced IL-8 production after overnight incubation by ELISA relative to dexamethasone,Other,21899328.0,
1107,626821,1,4,,103189031,5755,Active,,,0.10400000000000001,EC50,Antiinflammatory activity in human whole blood assessed as inhibition of IL-1beta-induced IL-8 production after overnight incubation by ELISA,Confirmatory,21899328.0,
1108,626822,1,4,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human whole blood assessed as inhibition of IL-1beta-induced IL-8 production after overnight incubation by ELISA relative to Dexamethasone,Other,21899328.0,
1109,626838,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, po administered as a single dose 2 hrs before carrageenan challenge measured 4 hrs post carrageenan challenge by plethysmometry relative to control",Other,21899328.0,
1110,626843,1,3,,103189031,5755,Active,,,,,"Antiinflammatory activity in Freund's complete adjuvant-induced Lewis rat arthritis model assessed as reduction in paw swelling at 5 mg/kg/day, po qd for 21 days",Other,21899328.0,
1111,626847,1,9,,103189031,5755,Unspecified,126885.0,4306.0,,,Agonist activity at human mineralocorticoid receptor expressed in human A549 cells by fluorescence polarization assay relative to aldosterone,Other,21899328.0,
1112,640508,4,5,,103189031,5755,Active,121069.0,2908.0,0.0077,IC50,Transrepression activity at glucocorticoid receptor in human H292 cells assessed as inhibition of TNF-stimulated IL-8 production,Confirmatory,22197391.0,
1113,640509,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in human H292 cells assessed as inhibition of TNF-stimulated IL-8 production at 1 uM relative to prednisolone,Other,22197391.0,
1114,640510,1,9,,103189031,5755,Active,1169883.0,24413.0,0.0654,IC50,Transactivation of glucocorticoid receptor in rat H42E cells assessed as induction of TAT measuring degradation of tyrosine to p-hydroxy phenyl pyruvate,Confirmatory,22197391.0,
1115,640511,1,9,,103189031,5755,Unspecified,1169883.0,24413.0,,,Transactivation of glucocorticoid receptor in rat H42E cells assessed as induction of TAT measuring degradation of tyrosine to p-hydroxy phenyl pyruvate at 1 uM relative to prednisolone,Other,22197391.0,
1116,640512,1,9,,103189031,5755,Active,121069.0,2908.0,0.34,IC50,Transactivation of glucocorticoid receptor in human HepG2 cells assessed as induction of TAT measuring degradation of tyrosine to p-hydroxy phenyl pyruvate,Confirmatory,22197391.0,
1117,640513,1,9,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation of glucocorticoid receptor in human HepG2 cells assessed as induction of TAT measuring degradation of tyrosine to p-hydroxy phenyl pyruvate at 1 uM relative to untreated control,Other,22197391.0,
1118,640514,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against Brown Norway rat allergic lung inflammation model assessed as total cell inhibition at 10 mg/kg, po for 3 days",Other,22197391.0,
1119,640515,1,3,,103189031,5755,Unspecified,,,,,"Toxicity in Brown Norway rat allergic lung inflammation model assessed as decrease in thymus weight at 10 mg/kg, po for 3 days",Other,22197391.0,
1120,640516,3,2,,103189031,5755,Unspecified,,,,,"AUC in Brown Norway rat at at 10 mg/kg, po",Other,22197391.0,
1121,640607,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in ovalbumin-induced allergic Brown Norway rat lung inflammation model assessed as inhibition of forced vital capacity at 3 mg/kg, po qd administered 3 days before ovalbumin-challenge measured 24 hrs of post ovalbumin challenge",Other,22197391.0,
1122,640608,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in ovalbumin-induced allergic Brown Norway rat lung inflammation model assessed as inhibition of forced vital capacity at 10 mg/kg, po qd administered 3 days before ovalbumin-challenge measured 24 hrs of post ovalbumin challenge",Other,22197391.0,
1123,640609,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in ovalbumin-induced allergic Brown Norway rat lung inflammation model assessed as inhibition of forced vital capacity at 30 mg/kg, po qd administered 3 days before ovalbumin-challenge measured 24 hrs of post ovalbumin challenge",Other,22197391.0,
1124,640610,3,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in po dosed ovalbumin-induced allergic Brown Norway rat lung inflammation model assessed as inhibition of forced vital capacity administered 3 days before ovalbumin-challenge measured 24 hrs of post ovalbumin challenge,Other,22197391.0,
1125,640612,1,3,,103189031,5755,Active,,,,,"Antiinflammatory activity in rat assessed as inhibition of LPS-induced TNF-alpha secretion at 3 mg/kg, po",Other,22197391.0,
1126,651548,1,1,,85788424,5755,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1127,651550,1,1,,50085972,5755,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1128,651560,1,1,,56463372,5755,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1129,651572,1,2,,56463372,5755,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1130,651582,1,1,,56463372,5755,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1131,651602,1,1,,56463372,5755,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1132,651602,1,1,,56463372,5755,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1133,651602,1,1,,56463372,5755,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1134,651631,4,1,,144204880,5755,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1135,651631,4,1,,144208871,5755,Inconclusive,269849759.0,7157.0,21.3815,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1136,651631,4,1,,144213304,5755,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1137,651632,4,1,,144204880,5755,Inconclusive,296439460.0,79915.0,0.015,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1138,651632,4,1,,144208871,5755,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1139,651632,4,1,,144213304,5755,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1140,651633,4,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1141,651633,4,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1142,651633,4,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1143,651634,4,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1144,651634,4,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1145,651634,4,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1146,651635,1,3,,50085972,5755,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1147,651636,1,1,,56463372,5755,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1148,651640,1,1,,56463372,5755,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1149,651644,1,1,,50085972,5755,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1150,651647,1,1,,56463372,5755,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1151,651654,1,1,,56463372,5755,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1152,651658,1,1,,56463372,5755,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1153,651661,2,1,,56463372,5755,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1154,651687,1,1,,56463372,5755,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1155,651699,1,1,,56463372,5755,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1156,651699,1,1,,56463372,5755,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1157,651702,1,2,,56463372,5755,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1158,651704,2,1,,56463372,5755,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1159,651710,1,1,,56463372,5755,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1160,651711,2,1,,56463372,5755,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1161,651718,1,2,,56463372,5755,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1162,651723,1,1,,56463372,5755,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1163,651724,1,1,,50085972,5755,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1164,651725,1,1,,50085972,5755,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1165,651768,1,2,,50085972,5755,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1166,651800,1,1,,56463372,5755,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1167,651819,1,1,,50085972,5755,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1168,651820,1,1,,50085972,5755,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1169,651821,2,4,,56463372,5755,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1170,651828,1,2,,92309181,5755,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1171,651828,1,2,,121362434,5755,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1172,651957,1,1,,56463372,5755,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1173,651958,1,1,,56463372,5755,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1174,651965,1,1,,50085972,5755,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1175,651999,1,1,,56463372,5755,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1176,652010,1,1,,56463372,5755,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1177,652017,1,1,,56463372,5755,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1178,652025,1,1,,50085972,5755,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1179,652039,1,1,,56463372,5755,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1180,652048,1,2,,50085972,5755,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1181,652048,1,2,,144204880,5755,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1182,652051,1,1,,50085972,5755,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1183,652051,1,1,,144204880,5755,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1184,652054,1,1,,50085972,5755,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1185,652067,1,4,,56463372,5755,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1186,652104,1,1,,50085972,5755,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1187,652105,1,1,,50085972,5755,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1188,652106,1,1,,50085972,5755,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1189,652115,1,1,,56463372,5755,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1190,652126,1,3,,56463372,5755,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1191,652154,1,1,,56463372,5755,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1192,652162,2,1,,56463372,5755,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1193,652163,1,1,,56463372,5755,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1194,652197,1,1,,56463372,5755,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1195,652257,1,1,,56463372,5755,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1196,656150,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma PAI-1 level at 10 mg/kg, po administered 2 hrs before LPS challenge",Other,22386529.0,
1197,656151,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma IL-6 level at 10 mg/kg, po administered 2 hrs before LPS challenge",Other,22386529.0,
1198,656152,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma MCP-1 level at 10 mg/kg, po administered 2 hrs before LPS challenge",Other,22386529.0,
1199,656153,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in LPS-stimulated acute inflammation BALB/c mouse model assessed as inhibition of plasma TNF-alpha level at 10 mg/kg, po administered 2 hrs before LPS challenge",Other,22386529.0,
1200,659505,3,2,,103189031,5755,Unspecified,,,,,AUC in po dosed rat,Other,22465636.0,
1201,659506,2,2,,103189031,5755,Unspecified,,,,,Cmax in po dosed rat,Other,22465636.0,
1202,659507,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in Brown Norway rat lung inflammation model assessed as total cell inhibition at 10 mg/kg, po for 3 days",Other,22465636.0,
1203,659509,1,2,,103189031,5755,Unspecified,,,,,"Transactivation activity in Brown Norway rat lung inflammation model assessed as thymolysis measuring decrease in thymus weight at 10 mg/kg, po for 3 days",Other,22465636.0,
1204,661541,1,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human RBC assessed as membrane stabilization at 10 ug/mL after 30 mins by UV-Visible spectrophotometry,Other,22542015.0,
1205,661542,1,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human RBC assessed as membrane stabilization at 50 ug/mL after 30 mins by UV-Visible spectrophotometry,Other,22542015.0,
1206,661543,1,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human RBC assessed as membrane stabilization at 100 ug/mL after 30 mins by UV-Visible spectrophotometry,Other,22542015.0,
1207,661544,1,2,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in human RBC assessed as membrane stabilization at 200 ug/mL after 30 mins by UV-Visible spectrophotometry,Other,22542015.0,
1208,678781,1,8,,103189031,5755,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,12379510.0,
1209,679082,1,8,,103189031,5755,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Prednisolone at a concentration of 20 uM in MDR1-expressing MDCK cells,Other,12948019.0,
1210,679083,1,8,,103189031,5755,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Prednisolone at a concentration of 20 uM in Caco-2 cells,Other,12948019.0,
1211,680437,1,8,,103189031,5755,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, Prednisolone: 100 uM) in Xenopus laevis oocytes",Other,8786566.0,
1212,681136,1,8,,103189031,5755,Unspecified,27735248.0,80899.0,,,TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells,Other,10101033.0,
1213,681354,1,8,,103189031,5755,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells,Other,14661924.0,
1214,686940,1,1,,56463372,5755,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1215,686964,1,1,,56463372,5755,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1216,686970,1,2,,50085972,5755,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1217,686971,1,2,,50085972,5755,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1218,686977,2,1,,49698415,5755,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1219,686978,1,1,,50085972,5755,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1220,686978,1,1,,144204880,5755,Inconclusive,79154014.0,55775.0,13.3359,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1221,686979,1,1,,50085972,5755,Inconclusive,79154014.0,55775.0,7.3078,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1222,686979,1,1,,144204880,5755,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1223,686992,2,1,,56463372,5755,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1224,686996,1,1,,56463372,5755,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1225,687014,1,1,,56463372,5755,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1226,687016,1,1,,56463372,5755,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1227,699539,1,7,,103189031,5755,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1228,699540,1,7,,103189031,5755,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1229,699541,1,7,,103189031,5755,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1230,699957,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as reduction in shortening of colon at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1231,699959,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as prevention of body weigth loss at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1232,699968,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as reduction in histological colon damage score at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1233,699974,1,2,,103189031,5755,Active,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as reduction in TNFalpha level at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1234,699975,1,2,,103189031,5755,Active,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as reduction in IL6 level at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1235,699976,1,2,,103189031,5755,Active,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as reduction in IL1b level at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1236,700171,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as decrease in myeloperoxidative activity at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1237,700174,1,2,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity against DSS-induced colitis BALB/c mouse model assessed as decrease in disease activity index at 5 mg/kg, po qd for 7 days measured on day 7 relative to vehicle-treated control",Other,22663546.0,
1238,720504,1,1,,50085972,5755,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1239,720508,1,1,,56463372,5755,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1240,720509,1,1,,56463372,5755,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1241,720511,1,1,,56463372,5755,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1242,720516,2,1,,144204880,5755,Inconclusive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1243,720516,2,1,,144208871,5755,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1244,720516,2,1,,144213304,5755,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1245,720522,1,1,,50085972,5755,Inactive,122893032.0,,,Potency,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,Confirmatory,,
1246,720523,1,1,,50085972,5755,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,Confirmatory,,
1247,720524,1,1,,50085972,5755,Active,224028257.0,4780.0,0.0731,Potency,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Confirmatory,,
1248,720532,1,1,,144204880,5755,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1249,720533,1,1,,144204880,5755,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1250,720542,1,2,,50085972,5755,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1251,720543,1,1,,56463372,5755,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1252,720551,1,2,,50085972,5755,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1253,720552,2,1,,144204880,5755,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1254,720552,2,1,,144208871,5755,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1255,720552,2,1,,144213304,5755,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1256,720553,1,2,,50085972,5755,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1257,720554,1,3,,121362434,5755,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
1258,720579,2,1,,50085972,5755,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1259,720579,2,1,,144204880,5755,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1260,720580,1,1,,50085972,5755,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1261,720580,1,1,,144204880,5755,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1262,720582,1,1,,56463372,5755,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1263,720596,1,1,,56463372,5755,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1264,720634,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1265,720634,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1266,720634,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1267,720635,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1268,720635,2,1,,144208871,5755,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1269,720635,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1270,720637,2,1,,144204880,5755,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1271,720637,2,1,,144208871,5755,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1272,720637,2,1,,144213304,5755,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1273,720641,1,2,,92309181,5755,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1274,720647,1,2,,56463372,5755,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1275,720648,1,1,,56463372,5755,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1276,720674,2,2,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1277,720674,2,2,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1278,720674,2,2,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1279,720675,2,2,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1280,720675,2,2,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1281,720675,2,2,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1282,720678,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1283,720678,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1284,720678,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1285,720679,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1286,720679,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1287,720679,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1288,720680,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1289,720680,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1290,720680,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1291,720681,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1292,720681,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1293,720681,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1294,720682,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1295,720682,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1296,720682,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1297,720683,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1298,720683,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1299,720683,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1300,720684,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1301,720684,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1302,720684,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1303,720685,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1304,720685,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1305,720685,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1306,720686,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1307,720686,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1308,720686,2,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1309,720687,2,2,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1310,720687,2,2,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1311,720687,2,2,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1312,720691,4,1,,144204880,5755,Active,311348376.0,2908.0,0.0535,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1313,720691,4,1,,144208871,5755,Active,311348376.0,2908.0,0.0171,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1314,720691,4,1,,144213304,5755,Active,311348376.0,2908.0,0.0219,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1315,720692,3,1,,144204880,5755,Inconclusive,311348376.0,2908.0,0.0849,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1316,720692,3,1,,144208871,5755,Inconclusive,311348376.0,2908.0,0.0136,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1317,720692,3,1,,144213304,5755,Inconclusive,311348376.0,2908.0,0.0309,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1318,720693,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1319,720693,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1320,720693,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1321,720700,1,4,,56463372,5755,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1322,720702,1,1,,56463372,5755,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1323,720704,1,4,,56463372,5755,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1324,720706,1,2,,56463372,5755,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1325,720707,1,2,,50085972,5755,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1326,720708,1,2,,50085972,5755,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1327,720709,1,2,,50085972,5755,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1328,720711,1,2,,50085972,5755,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1329,720717,1,3,,92125114,5755,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1330,720717,1,3,,92309181,5755,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1331,720719,2,1,,144204880,5755,Active,311348376.0,2908.0,0.055632299999999996,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1332,720719,2,1,,144208871,5755,Active,311348376.0,2908.0,0.031672700000000005,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1333,720719,2,1,,144213304,5755,Active,311348376.0,2908.0,0.0236202,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1334,720725,2,1,,144204880,5755,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1335,720725,2,1,,144208871,5755,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1336,720725,2,1,,144213304,5755,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1337,740301,1,6,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation of glucocorticoid receptor in HEK293 cells co-transfected with GRE assessed as induction of GRE-dependent gene expression after 6 hrs by luciferase reporter gene assay,Other,23498916.0,
1338,743012,3,1,,144204880,5755,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1339,743012,3,1,,144208871,5755,Inconclusive,,,1.3491,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1340,743012,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1341,743014,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1342,743014,3,1,,144208871,5755,Inconclusive,,,33.8874,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1343,743014,3,1,,144213304,5755,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1344,743015,3,1,,144204880,5755,Inconclusive,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1345,743015,3,1,,144208871,5755,Inconclusive,,,67.6143,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1346,743015,3,1,,144213304,5755,Inconclusive,,,13.6854,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1347,743033,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1348,743033,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1349,743033,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1350,743035,2,1,,144204880,5755,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1351,743035,2,1,,144208871,5755,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1352,743035,2,1,,144213304,5755,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1353,743036,2,1,,144204880,5755,Active,124375976.0,367.0,0.0849,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1354,743036,2,1,,144208871,5755,Active,124375976.0,367.0,0.0483,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1355,743036,2,1,,144213304,5755,Active,124375976.0,367.0,0.0389,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1356,743040,3,1,,144204880,5755,Active,124375976.0,367.0,0.0841,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1357,743040,3,1,,144208871,5755,Active,124375976.0,367.0,0.0676,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1358,743040,3,1,,144213304,5755,Active,124375976.0,367.0,0.0386,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1359,743041,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1360,743041,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1361,743041,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1362,743042,3,1,,144204880,5755,Inactive,124375976.0,367.0,0.0668,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1363,743042,3,1,,144208871,5755,Inactive,124375976.0,367.0,0.0269,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1364,743042,3,1,,144213304,5755,Inactive,124375976.0,367.0,0.0344,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1365,743053,2,1,,144204880,5755,Active,124375976.0,367.0,0.072777,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1366,743053,2,1,,144208871,5755,Active,124375976.0,367.0,0.05487140000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1367,743053,2,1,,144213304,5755,Active,124375976.0,367.0,0.029736000000000002,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1368,743054,2,1,,144204880,5755,Inconclusive,124375976.0,367.0,0.195704,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1369,743054,2,1,,144208871,5755,Inconclusive,124375976.0,367.0,0.044330699999999994,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1370,743054,2,1,,144213304,5755,Inconclusive,124375976.0,367.0,0.0357211,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1371,743063,2,1,,144204880,5755,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1372,743063,2,1,,144208871,5755,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1373,743063,2,1,,144213304,5755,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1374,743064,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1375,743064,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1376,743064,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1377,743065,3,1,,144204880,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1378,743065,3,1,,144208871,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1379,743065,3,1,,144213304,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1380,743066,3,1,,144204880,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1381,743066,3,1,,144208871,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1382,743066,3,1,,144213304,5755,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1383,743067,2,1,,144204880,5755,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1384,743067,2,1,,144208871,5755,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1385,743067,2,1,,144213304,5755,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1386,743069,2,1,,144204880,5755,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1387,743069,2,1,,144208871,5755,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1388,743069,2,1,,144213304,5755,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1389,743074,2,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1390,743074,2,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1391,743074,2,1,,144213304,5755,Inconclusive,,,3.89,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1392,743075,2,1,,144204880,5755,Inconclusive,348019627.0,2099.0,1.6914,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1393,743075,2,1,,144208871,5755,Inactive,348019627.0,2099.0,48.308,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1394,743075,2,1,,144213304,5755,Inactive,348019627.0,2099.0,13.8022,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1395,743077,2,1,,144204880,5755,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1396,743077,2,1,,144208871,5755,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1397,743077,2,1,,144213304,5755,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1398,743078,2,1,,144204880,5755,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1399,743078,2,1,,144208871,5755,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1400,743078,2,1,,144213304,5755,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1401,743079,3,1,,144204880,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1402,743079,3,1,,144208871,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1403,743079,3,1,,144213304,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1404,743080,3,1,,144204880,5755,Inconclusive,348019627.0,2099.0,0.4731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1405,743080,3,1,,144208871,5755,Inconclusive,348019627.0,2099.0,0.0603,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1406,743080,3,1,,144213304,5755,Inconclusive,348019627.0,2099.0,0.0172,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1407,743081,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1408,743081,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1409,743081,3,1,,144213304,5755,Inconclusive,,,0.0193,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1410,743083,3,1,,144204880,5755,Inactive,119597822.0,1588.0,0.0531,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1411,743083,3,1,,144208871,5755,Inactive,119597822.0,1588.0,0.0339,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1412,743083,3,1,,144213304,5755,Inactive,119597822.0,1588.0,0.0306,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1413,743084,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1414,743084,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1415,743084,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1416,743085,3,1,,144204880,5755,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1417,743085,3,1,,144208871,5755,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1418,743085,3,1,,144213304,5755,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1419,743086,3,1,,144204880,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1420,743086,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1421,743086,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1422,743091,2,1,,144204880,5755,Inconclusive,348019627.0,2099.0,0.281796,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1423,743091,2,1,,144208871,5755,Inconclusive,348019627.0,2099.0,0.060261300000000004,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1424,743091,2,1,,144213304,5755,Inconclusive,348019627.0,2099.0,0.0416478,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1425,743094,3,1,,144204880,5755,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1426,743094,3,1,,144208871,5755,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1427,743094,3,1,,144213304,5755,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1428,743122,2,1,,144204880,5755,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1429,743122,2,1,,144208871,5755,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1430,743122,2,1,,144213304,5755,Inconclusive,51095037.0,196.0,0.00611306,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1431,743126,1,1,,56463372,5755,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1432,743139,2,1,,144204880,5755,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1433,743139,2,1,,144208871,5755,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1434,743139,2,1,,144213304,5755,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1435,743140,2,1,,144204880,5755,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1436,743140,2,1,,144208871,5755,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1437,743140,2,1,,144213304,5755,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1438,743191,3,1,,144208871,5755,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1439,743191,3,1,,144213304,5755,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1440,743191,3,1,,170464732,5755,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1441,743194,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1442,743194,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1443,743194,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1444,743199,2,1,,144208871,5755,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1445,743199,2,1,,144213304,5755,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1446,743199,2,1,,170464732,5755,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1447,743202,4,1,,144208871,5755,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1448,743202,4,1,,144213304,5755,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1449,743202,4,1,,170464732,5755,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1450,743203,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1451,743203,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1452,743203,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1453,743209,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1454,743209,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1455,743209,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1456,743210,4,1,,144208871,5755,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1457,743210,4,1,,144213304,5755,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1458,743210,4,1,,170464732,5755,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1459,743211,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1460,743211,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1461,743211,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1462,743212,3,1,,144208871,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1463,743212,3,1,,144213304,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1464,743212,3,1,,170464732,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1465,743213,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1466,743213,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1467,743213,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1468,743215,3,1,,144208871,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1469,743215,3,1,,144213304,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1470,743215,3,1,,170464732,5755,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1471,743217,3,1,,144208871,5755,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1472,743217,3,1,,144213304,5755,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1473,743217,3,1,,170464732,5755,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1474,743218,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1475,743218,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1476,743218,3,1,,170464732,5755,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1477,743219,3,1,,144208871,5755,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1478,743219,3,1,,144213304,5755,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1479,743219,3,1,,170464732,5755,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1480,743220,3,1,,144208871,5755,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1481,743220,3,1,,144213304,5755,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1482,743220,3,1,,170464732,5755,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1483,743221,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1484,743221,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1485,743221,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1486,743222,3,1,,144208871,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1487,743222,3,1,,144213304,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1488,743222,3,1,,170464732,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1489,743223,3,1,,144208871,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1490,743223,3,1,,144213304,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1491,743223,3,1,,170464732,5755,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1492,743224,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1493,743224,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1494,743224,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1495,743225,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1496,743225,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1497,743225,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1498,743226,2,1,,144208871,5755,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1499,743226,2,1,,144213304,5755,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1500,743226,2,1,,170464732,5755,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1501,743227,2,1,,144208871,5755,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1502,743227,2,1,,144213304,5755,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1503,743227,2,1,,170464732,5755,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1504,743228,3,1,,144208871,5755,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1505,743228,3,1,,144213304,5755,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1506,743228,3,1,,170464732,5755,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1507,743238,1,1,,56463372,5755,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1508,743239,2,1,,144208871,5755,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1509,743239,2,1,,144213304,5755,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1510,743239,2,1,,170464732,5755,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1511,743240,2,1,,144208871,5755,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1512,743240,2,1,,144213304,5755,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1513,743240,2,1,,170464732,5755,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1514,743241,2,1,,144208871,5755,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1515,743241,2,1,,144213304,5755,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1516,743241,2,1,,170464732,5755,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1517,743242,2,1,,144208871,5755,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1518,743242,2,1,,144213304,5755,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1519,743242,2,1,,170464732,5755,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1520,743244,1,1,,144204880,5755,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1521,743247,1,2,,56463372,5755,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1522,743255,1,1,,50085972,5755,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1523,743266,1,2,,50085972,5755,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1524,743268,1,1,,172080596,5755,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
1525,743269,1,1,,56463372,5755,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1526,743269,1,1,,56463372,5755,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1527,743270,1,1,,172080596,5755,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1528,743271,1,1,,172080596,5755,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
1529,743272,1,1,,172080596,5755,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
1530,743279,1,2,,50085972,5755,Active,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1531,743287,1,1,,56463372,5755,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1532,743397,1,1,,56463372,5755,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1533,743398,1,1,,56463372,5755,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1534,768804,1,3,,103189031,5755,Unspecified,,,,,"In vivo inhibition of PGE2 in albino rat plasma at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs by EIA relative to control",Other,,
1535,768805,1,3,,103189031,5755,Unspecified,,,,,"In vivo inhibition of PGE2 in albino rat plasma at 25 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs by EIA relative to control",Other,,
1536,768806,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as protection against carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs relative to control",Other,,
1537,768807,1,3,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as protection against carrageenan-induced paw edema at 25 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs relative to control",Other,,
1538,780045,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in mouse assessed as change in body weight at 3 mg/kg, po qd after 20 days relative to untreated control",Other,24075731.0,
1539,780047,1,1,,103189031,5755,Active,,,,,"Antiinflammatory activity in collagen-induced arthritis mouse model at 3 mg/kg, po qd after 20 days",Other,24075731.0,
1540,932038,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020513,Other,,
1541,932039,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020513,Other,,
1542,932040,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020513,Other,,
1543,932041,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020513,Other,,
1544,932042,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020513,Other,,
1545,932043,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020513,Other,,
1546,932044,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020513,Other,,
1547,932045,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020513,Other,,
1548,932046,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020513,Other,,
1549,932047,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020513,Other,,
1550,932048,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020513,Other,,
1551,932049,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020513,Other,,
1552,932050,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020513,Other,,
1553,932051,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020513,Other,,
1554,932052,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020513,Other,,
1555,932053,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020513,Other,,
1556,932054,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020513",Other,,
1557,932055,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020513,Other,,
1558,932056,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020513,Other,,
1559,949151,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020513,Other,,
1560,949152,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020513,Other,,
1561,949153,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020513,Other,,
1562,949154,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020513,Other,,
1563,949155,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020513,Other,,
1564,949156,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020513,Other,,
1565,949157,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020513,Other,,
1566,949158,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020513,Other,,
1567,949159,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020513,Other,,
1568,949160,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020513,Other,,
1569,949161,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020513,Other,,
1570,949162,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020513,Other,,
1571,949163,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020513",Other,,
1572,949164,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020513,Other,,
1573,949165,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020513,Other,,
1574,949166,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020513,Other,,
1575,949167,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020513,Other,,
1576,949168,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020513,Other,,
1577,949169,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020513,Other,,
1578,966149,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020513,Other,,
1579,966150,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020513,Other,,
1580,966151,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020513,Other,,
1581,966152,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020513,Other,,
1582,966153,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020513,Other,,
1583,966154,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020513,Other,,
1584,966587,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020513,Other,,
1585,966588,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020513,Other,,
1586,966589,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020513,Other,,
1587,966590,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020513,Other,,
1588,966591,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020513,Other,,
1589,966592,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020513,Other,,
1590,966593,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020513,Other,,
1591,966594,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020513,Other,,
1592,966595,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020513,Other,,
1593,966596,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020513,Other,,
1594,966597,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020513,Other,,
1595,966598,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020513,Other,,
1596,966599,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020513,Other,,
1597,973745,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020513,Other,,
1598,973746,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020513,Other,,
1599,973747,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020513,Other,,
1600,973748,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020513,Other,,
1601,973749,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020513,Other,,
1602,973750,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020513,Other,,
1603,973751,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020513,Other,,
1604,973752,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020513,Other,,
1605,973753,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020513,Other,,
1606,973754,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020513,Other,,
1607,973755,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020513,Other,,
1608,973756,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020513,Other,,
1609,973757,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020513,Other,,
1610,973758,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020513,Other,,
1611,973759,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020513,Other,,
1612,973760,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020513,Other,,
1613,973761,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020513,Other,,
1614,973762,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020513,Other,,
1615,973763,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020513,Other,,
1616,977599,1,1,,103189031,5755,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1617,977602,1,2,,103189031,5755,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1618,1010717,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1619,1010718,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020513",Other,,
1620,1010719,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020513",Other,,
1621,1010720,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020513",Other,,
1622,1010721,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1623,1010722,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1624,1010723,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1625,1010724,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020513,Other,,
1626,1010725,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020513",Other,,
1627,1010726,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020513,Other,,
1628,1010727,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020513",Other,,
1629,1010728,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1630,1010729,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020513",Other,,
1631,1010730,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020513",Other,,
1632,1010731,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1633,1010732,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1634,1010733,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020513",Other,,
1635,1010734,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020513",Other,,
1636,1010735,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1637,1011319,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1638,1011320,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1639,1011321,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1640,1011322,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1641,1011323,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1642,1011324,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1643,1011325,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020513",Other,,
1644,1011326,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1645,1011327,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1646,1011328,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020513",Other,,
1647,1011329,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1648,1011330,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020513,Other,,
1649,1011331,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020513,Other,,
1650,1011332,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020513",Other,,
1651,1011333,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1652,1011334,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020513",Other,,
1653,1011335,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020513,Other,,
1654,1011336,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1655,1013207,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1656,1013208,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1657,1013209,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020513",Other,,
1658,1013210,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020513",Other,,
1659,1013211,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020513,Other,,
1660,1013212,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1661,1013213,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020513",Other,,
1662,1013214,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020513",Other,,
1663,1013215,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1664,1013216,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020513",Other,,
1665,1013217,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020513",Other,,
1666,1013218,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020513",Other,,
1667,1013219,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020513,Other,,
1668,1013220,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1669,1013221,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020513",Other,,
1670,1013222,1,3,,103189031,5755,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020513,Other,,
1671,1013805,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1672,1013806,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020513",Other,,
1673,1013807,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1674,1013808,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1675,1013809,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1676,1013810,1,3,,103189031,5755,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020513",Other,,
1677,1053197,1,1,,56463372,5755,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1678,1071623,1,1,,103189031,5755,Active,,,,,"Antiinflammatory activity in Lewis rat collagen-induced arthritis model assessed as reduction in ankle diameter at 10 mg/kg, po administered for 15 days measured during compound dosing",Other,24446728.0,
1679,1071625,1,1,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in po dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced IL-1beta secretion incubated for 2 hrs prior to carrageenan challenge measured after 5 hrs by ELISA,Other,24446728.0,
1680,1071626,1,1,,103189031,5755,Unspecified,,,,,Antiinflammatory activity in po dosed Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema incubated for 2 hrs prior to carrageenan challenge measured after 5 hrs by ELISA,Other,24446728.0,
1681,1071633,1,1,,103189031,5755,Active,,,0.0082,IC50,Antiinflammatory activity in PMA-differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 60 mins prior to LPS challenge measured after 24 hrs,Confirmatory,24446728.0,
1682,1071634,1,1,,103189031,5755,Active,,,0.007259999999999999,IC50,Antiinflammatory activity in human CCD-39SK cells assessed as inhibition of IL-1beta-induced IL-6 production incubated for 60 mins prior to IL-1beta induction measured after 24 hrs,Confirmatory,24446728.0,
1683,1071635,1,4,,103189031,5755,Unspecified,121069.0,2908.0,,,Transactivation of human glucocorticoid receptor expressed in HEK293 cells at 10 uM after 24 hrs by luciferase reporter gene assay relative to control,Other,24446728.0,
1684,1071636,2,3,,103189031,5755,Unspecified,90110048.0,5241.0,10.0,Ki,Displacement of [3H]-methyltrienolone from human progesterone receptor expressed in HEK293 cells,Confirmatory,24446728.0,
1685,1071637,2,3,,103189031,5755,Active,1018618719.0,367.0,2.52,Ki,Displacement of [3H]-methyltrienolone from human androgen receptor expressed in HEK293 cells,Confirmatory,24446728.0,
1686,1071638,2,3,,103189031,5755,Active,121069.0,2908.0,0.00114,Ki,Displacement of [3H]-dexamethasone from human glucocorticoid receptor expressed in HEK293 cells,Confirmatory,24446728.0,
1687,1071639,2,3,,103189031,5755,Active,126885.0,4306.0,0.00029,Ki,Displacement of [3H]-aldosterone from human mineralocorticoid receptor expressed in HEK293 cells,Confirmatory,24446728.0,
1688,1075798,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in femur cortical thickness at 30 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1689,1075799,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in femur cortical thickness at 3 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1690,1075801,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in femur cortical thickness at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1691,1075802,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in femur cortical thickness at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1692,1075804,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in insulin level at 30 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1693,1075805,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in insulin level at 3 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1694,1075807,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in insulin level at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1695,1075808,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in insulin level at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1696,1075810,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in free fatty acid level at 30 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1697,1075811,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in free fatty acid level at 3 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1698,1075813,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in free fatty acid level at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1699,1075814,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in free fatty acid level at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1700,1075816,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in triglyceride level at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1701,1075817,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in triglyceride level at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1702,1075819,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in body fat at 30 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1703,1075820,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in body fat at 3 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1704,1075822,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in body fat at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1705,1075823,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in body fat at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1706,1075825,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in AUC at 30 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1707,1075826,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in AUC at 3 mg/kg, po qd for 35 days relative to 30% cremophor-treated control",Other,24506830.0,
1708,1075828,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in AUC at 30 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1709,1075829,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in collagen-induced B10.RIII mouse arthritis model assessed as change in AUC at 3 mg/kg, po qd for 35 days relative to 1% methylcellulose-treated control",Other,24506830.0,
1710,1075843,1,4,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human HMG-63 cells assessed as suppression of vitamin D-induced osteocalcin production at 2 uM after 48 hrs by Gla-type osteocalcin ELISA relative to dexomethasone,Other,24506830.0,
1711,1079931,1,1,,103189031,5755,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1712,1079932,1,1,,103189031,5755,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1713,1079933,1,1,,103189031,5755,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1714,1079934,1,1,,103189031,5755,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1715,1079935,1,1,,103189031,5755,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1716,1079936,1,1,,103189031,5755,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1717,1079937,1,1,,103189031,5755,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1718,1079938,1,1,,103189031,5755,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1719,1079939,1,1,,103189031,5755,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1720,1079940,1,1,,103189031,5755,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1721,1079941,1,1,,103189031,5755,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1722,1079942,1,1,,103189031,5755,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1723,1079943,1,1,,103189031,5755,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1724,1079944,1,1,,103189031,5755,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1725,1079945,1,1,,103189031,5755,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1726,1079946,1,1,,103189031,5755,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1727,1079947,1,1,,103189031,5755,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1728,1079948,1,1,,103189031,5755,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1729,1079949,1,1,,103189031,5755,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1730,1091955,1,2,,103189031,5755,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
1731,1091956,1,1,,103189031,5755,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
1732,1091957,1,1,,103189031,5755,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
1733,1091958,2,1,,103189031,5755,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
1734,1115898,1,2,,103189031,5755,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) RBCs assessed as prevention of hemolysis at 200 ug/mL after 30 min by UV-Vis spectrophotometric analysis relative to control,Other,,
1735,1115899,1,2,,103189031,5755,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) RBCs assessed as prevention of hemolysis at 100 ug/mL after 30 min by UV-Vis spectrophotometric analysis relative to control,Other,,
1736,1115900,1,2,,103189031,5755,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) RBCs assessed as prevention of hemolysis at 50 ug/mL after 30 min by UV-Vis spectrophotometric analysis relative to control,Other,,
1737,1115901,1,2,,103189031,5755,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) RBCs assessed as prevention of hemolysis at 10 ug/mL after 30 min by UV-Vis spectrophotometric analysis relative to control,Other,,
1738,1117298,1,2,,170464732,5755,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1739,1117304,1,2,,170464732,5755,Inactive,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1740,1117305,1,2,,170464732,5755,Inactive,,,7.0795,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1741,1117310,1,1,,170464732,5755,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1742,1117312,1,1,,170464732,5755,Inactive,,,7.079460000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1743,1117314,1,1,,170464732,5755,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1744,1117326,1,1,,170464732,5755,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1745,1117329,1,1,,170464732,5755,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1746,1117336,1,1,,170464732,5755,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1747,1117340,1,1,,170464732,5755,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1748,1117341,1,1,,170464732,5755,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1749,1117342,1,1,,170464732,5755,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1750,1117343,1,1,,170464732,5755,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1751,1117346,1,1,,170464732,5755,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1752,1125607,1,3,,103189031,5755,Active,121069.0,2908.0,0.015,IC50,Displacement of TAMRA-labeled dexamethasone from glucocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
1753,1125608,2,2,,103189031,5755,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of TAMRA-labeled mifepristone from progesterone receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
1754,1125609,1,3,,103189031,5755,Active,126885.0,4306.0,0.044000000000000004,IC50,Displacement of TAMRA-labeled dexamethasone from mineralocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
1755,1125610,1,3,,103189031,5755,Active,121069.0,2908.0,0.006,IC50,Agonist activity at glucocorticoid receptor in human foreskin fibroblasts assessed as inhibition of IL-1-induced IL-6 production by trans-repression assay,Confirmatory,24656565.0,
1756,1125611,1,3,,103189031,5755,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human foreskin fibroblasts assessed as inhibition of IL-1-induced IL-6 production at 2 uM by trans-repression assay relative to dexamethasone,Other,24656565.0,
1757,1125629,1,1,,103189031,5755,Unspecified,,,,,"Antiarthritic activity in B10.RIII mouse collagen/complete Freund's adjuvant-induced arthritis model assessed as reduction of disease score at 30 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1758,1125631,1,1,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha production at 3 mg/kg, po",Other,24656565.0,
1759,1125634,1,1,,103189031,5755,Unspecified,,,,,"Antiarthritic activity in B10.RIII mouse collagen/complete Freund's adjuvant-induced arthritis model assessed as reduction of disease score at 3 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1760,1125635,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as body fate level in serum at 30 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1761,1125637,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as body fate level in serum at 3 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1762,1125638,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as triglyceride level in serum at 30 mg/kg, po qd for 5 weeks relative to control",Other,,
1763,1125640,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as triglyceride level in serum at 3 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1764,1125641,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as free fatty acid level in serum at 30 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1765,1125643,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as free fatty acid level in serum at 3 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1766,1125644,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as insulin level in serum at 30 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1767,1125646,1,2,,103189031,5755,Unspecified,,,,,"Toxicity in B10.RIII mouse assessed as insulin level in serum at 3 mg/kg, po qd for 5 weeks relative to control",Other,24656565.0,
1768,1132664,1,2,,103189031,5755,Unspecified,,,,,Glucocorticoid activity in sc dosed bilaterally adrenalectomized rat assessed as glycogen deposition in liver administered for 5 days relative to cortisol,Other,660591.0,
1769,1135042,1,1,,103189031,5755,Unspecified,,,100.0,ED50,Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay,Confirmatory,118258.0,
1770,1135048,1,1,,103189031,5755,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as median survival time at 27 mg/kg, ip qd administered for 5 days (Rvb = 10 days)",Other,118258.0,
1771,1135055,1,1,,103189031,5755,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in C3D2F1/J mouse assessed as increase in life span at 27 mg/kg, ip qd administered for 5 days relative to control",Other,118258.0,
1772,1135063,1,1,,103189031,5755,Unspecified,,,,,"Toxicity in C3D2F1/J mouse allografted with mouse L1210 cells assessed as body weight change at 27 mg/kg, ip qd administered for 5 days measured on day 8 (Rvb = 1.81 +/- 0.79 g)",Other,118258.0,
1773,1159509,1,1,,144208871,5755,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1774,1159509,1,1,,144213304,5755,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1775,1159509,1,1,,170464732,5755,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1776,1159515,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1777,1159515,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1778,1159515,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1779,1159516,1,1,,144208871,5755,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1780,1159516,1,1,,144213304,5755,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1781,1159516,1,1,,170464732,5755,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1782,1159517,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1783,1159517,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1784,1159517,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1785,1159518,1,1,,144208871,5755,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1786,1159518,1,1,,144213304,5755,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1787,1159518,1,1,,170464732,5755,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1788,1159519,1,1,,144208871,5755,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1789,1159519,1,1,,144213304,5755,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1790,1159519,1,1,,170464732,5755,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1791,1159520,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1792,1159520,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1793,1159520,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1794,1159521,1,1,,144208871,5755,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1795,1159521,1,1,,144213304,5755,Inactive,15928672.0,19885.0,0.0172,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1796,1159521,1,1,,170464732,5755,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1797,1159523,1,1,,144208871,5755,Inconclusive,15928672.0,19885.0,0.16983900000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1798,1159523,1,1,,144213304,5755,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1799,1159523,1,1,,170464732,5755,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1800,1159524,1,1,,50085972,5755,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1801,1159524,1,1,,144204880,5755,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1802,1159525,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1803,1159525,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1804,1159525,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1805,1159526,1,1,,144208871,5755,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1806,1159526,1,1,,144213304,5755,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1807,1159526,1,1,,170464732,5755,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1808,1159527,1,1,,144208871,5755,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1809,1159527,1,1,,144213304,5755,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1810,1159527,1,1,,170464732,5755,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1811,1159528,1,1,,144208871,5755,Inconclusive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1812,1159528,1,1,,144213304,5755,Inconclusive,119627033.0,3725.0,54.9477,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1813,1159528,1,1,,170464732,5755,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1814,1159529,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1815,1159529,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1816,1159529,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1817,1159531,1,1,,144208871,5755,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1818,1159531,1,1,,144213304,5755,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1819,1159531,1,1,,170464732,5755,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1820,1159550,3,1,,252401864,5755,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
1821,1159551,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1822,1159551,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1823,1159551,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1824,1159552,1,1,,144208871,5755,Inactive,325495463.0,5914.0,3.8022,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1825,1159552,1,1,,144213304,5755,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1826,1159552,1,1,,170464732,5755,Inconclusive,325495463.0,5914.0,0.0008,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1827,1159553,2,1,,144208871,5755,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1828,1159553,2,1,,144213304,5755,Inactive,325495463.0,5914.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1829,1159553,2,1,,170464732,5755,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1830,1159555,1,1,,144208871,5755,Inconclusive,325495463.0,5914.0,3.80223,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1831,1159555,1,1,,144213304,5755,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1832,1159555,1,1,,170464732,5755,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1833,1159606,1,1,,56463372,5755,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1834,1159607,2,1,,312309717,5755,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1835,1159614,1,2,,170464732,5755,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1836,1159620,1,1,,103189031,5755,Active,,,,,Summary of drug indications.,Other,,
1837,1181711,1,1,,103189031,5755,Unspecified,,,,,"Antiinflammatory activity in Lewis rat assessed as inhibition of LPS-induced TNF-alpha production at 30 mg/kg, po administered 90 mins prior to LPS challenge measured after 90 mins relative to vehicle-treated control",Other,24980053.0,
1838,1210069,1,2,,103189031,5755,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
1839,1211791,1,1,,103189031,5755,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
1840,1211792,1,1,,103189031,5755,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
1841,1211793,1,1,,103189031,5755,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
1842,1211794,1,2,,103189031,5755,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
1843,1211796,1,1,,103189031,5755,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1844,1211797,1,1,,103189031,5755,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1845,1211798,1,1,,103189031,5755,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
1846,1224834,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1847,1224834,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1848,1224834,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1849,1224835,1,1,,144208871,5755,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1850,1224835,1,1,,144213304,5755,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1851,1224835,1,1,,170464732,5755,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1852,1224836,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1853,1224836,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1854,1224836,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1855,1224837,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1856,1224837,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1857,1224837,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1858,1224838,1,1,,144208871,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1859,1224838,1,1,,144213304,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1860,1224838,1,1,,170464732,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1861,1224839,1,1,,144208871,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1862,1224839,1,1,,144213304,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1863,1224839,1,1,,170464732,5755,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1864,1224840,3,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1865,1224840,3,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1866,1224840,3,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1867,1224841,3,1,,144208871,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1868,1224841,3,1,,144213304,5755,Inactive,325495545.0,2101.0,0.2731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1869,1224841,3,1,,170464732,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1870,1224842,3,1,,144208871,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1871,1224842,3,1,,144213304,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1872,1224842,3,1,,170464732,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1873,1224843,1,1,,144208871,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1874,1224843,1,1,,144213304,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1875,1224843,1,1,,170464732,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1876,1224844,1,1,,144208871,5755,Inconclusive,,,27.1656,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1877,1224844,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1878,1224844,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1879,1224845,1,1,,144208871,5755,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1880,1224845,1,1,,144213304,5755,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1881,1224845,1,1,,170464732,5755,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1882,1224846,1,1,,144208871,5755,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1883,1224846,1,1,,144213304,5755,Inconclusive,11995455.0,3091.0,7.7616,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1884,1224846,1,1,,170464732,5755,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1885,1224847,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1886,1224847,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1887,1224847,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1888,1224848,3,1,,144208871,5755,Inconclusive,325495545.0,2101.0,30.2022,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1889,1224848,3,1,,144213304,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1890,1224848,3,1,,170464732,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1891,1224849,3,1,,144208871,5755,Inactive,325495545.0,2101.0,26.9177,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1892,1224849,3,1,,144213304,5755,Inactive,325495545.0,2101.0,9.6885,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1893,1224849,3,1,,170464732,5755,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1894,1224857,2,1,,170464732,5755,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1895,1224859,2,1,,170464732,5755,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1896,1224863,1,1,,176484442,5755,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1897,1224863,1,1,,176484813,5755,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1898,1224865,1,2,,56463372,5755,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1899,1224867,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1900,1224867,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1901,1224867,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1902,1224868,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1903,1224868,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1904,1224868,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1905,1224869,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1906,1224869,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1907,1224869,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1908,1224870,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1909,1224870,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1910,1224870,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1911,1224871,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1912,1224871,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1913,1224871,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1914,1224872,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1915,1224872,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1916,1224872,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1917,1224873,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1918,1224873,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1919,1224873,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1920,1224874,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1921,1224874,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1922,1224874,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1923,1224875,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1924,1224875,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1925,1224875,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1926,1224876,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1927,1224876,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1928,1224876,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1929,1224877,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1930,1224877,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1931,1224877,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1932,1224878,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1933,1224878,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1934,1224878,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1935,1224879,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1936,1224879,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1937,1224879,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1938,1224880,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1939,1224880,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1940,1224880,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1941,1224881,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1942,1224881,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1943,1224881,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1944,1224882,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1945,1224882,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1946,1224882,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1947,1224883,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1948,1224883,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1949,1224883,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1950,1224884,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1951,1224884,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1952,1224884,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1953,1224885,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1954,1224885,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1955,1224885,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1956,1224886,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1957,1224886,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1958,1224886,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1959,1224887,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1960,1224887,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1961,1224887,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1962,1224888,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1963,1224888,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1964,1224888,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1965,1224889,1,1,,144208871,5755,Active,,,21.5784,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1966,1224889,1,1,,144213304,5755,Active,,,19.4962,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1967,1224889,1,1,,170464732,5755,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1968,1224890,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1969,1224890,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1970,1224890,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1971,1224892,1,1,,144208871,5755,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1972,1224892,1,1,,144213304,5755,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1973,1224892,1,1,,170464732,5755,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1974,1224893,1,1,,144208871,5755,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1975,1224893,1,1,,144213304,5755,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1976,1224893,1,1,,170464732,5755,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1977,1224894,1,1,,144208871,5755,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1978,1224894,1,1,,144213304,5755,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1979,1224894,1,1,,170464732,5755,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1980,1224895,1,1,,144208871,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1981,1224895,1,1,,144213304,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1982,1224895,1,1,,170464732,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1983,1224896,1,1,,144208871,5755,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1984,1224896,1,1,,144213304,5755,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1985,1224896,1,1,,170464732,5755,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1986,1224905,2,1,,92309181,5755,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1987,1224905,2,1,,92309181,5755,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1988,1258395,1,1,,103189031,5755,Active,,,0.0042,IC50,BindingDB_Patents: Fluorescence Polarization Ligand Binding Assay. The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-length glucocorticoid (GR) protein. Reagents for this assay are purchased from Invitrogen in a test kit. A fluorescent labeled GR ligand is used as a fluorescent tracer and test compounds compete with the fluorescent tracer for GR binding. The change in polarization value in the presence of test compounds is due to binding of test compounds to GR and is used to determine IC50 and relative binding affinity of test compounds for GR.,Confirmatory,,
1989,1258396,1,1,,103189031,5755,Active,,,0.0149,IC50,BindingDB_Patents: Fluorescence Polarization Ligand Binding Assay. The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-length glucocorticoid (GR) protein. Reagents for this assay are purchased from Invitrogen in a test kit. A fluorescent labeled GR ligand is used as a fluorescent tracer and test compounds compete with the fluorescent tracer for GR binding. The change in polarization value in the presence of test compounds is due to binding of test compounds to GR and is used to determine IC50 and relative binding affinity of test compounds for GR.,Confirmatory,,
1990,1258397,1,1,,103189031,5755,Active,,,0.000526,IC50,BindingDB_Patents: Fluorescence Polarization Ligand Binding Assay. The glucocorticoid receptor fluorescence polarization ligand binding (GRFP) assay is used to evaluate direct binding of testing compounds to full-length glucocorticoid (GR) protein. Reagents for this assay are purchased from Invitrogen in a test kit. A fluorescent labeled GR ligand is used as a fluorescent tracer and test compounds compete with the fluorescent tracer for GR binding. The change in polarization value in the presence of test compounds is due to binding of test compounds to GR and is used to determine IC50 and relative binding affinity of test compounds for GR.,Confirmatory,,
1991,1259241,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1992,1259241,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1993,1259241,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1994,1259242,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1995,1259242,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1996,1259242,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1997,1259243,1,1,,144208871,5755,Inactive,124375976.0,367.0,0.0676,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1998,1259243,1,1,,144213304,5755,Inactive,124375976.0,367.0,0.6113,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1999,1259243,1,1,,170464732,5755,Inactive,124375976.0,367.0,0.1059,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2000,1259244,1,1,,144208871,5755,Inactive,348019627.0,2099.0,0.302,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2001,1259244,1,1,,144213304,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2002,1259244,1,1,,170464732,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2003,1259247,1,1,,144208871,5755,Inconclusive,124375976.0,367.0,0.0702595,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2004,1259247,1,1,,144213304,5755,Inconclusive,124375976.0,367.0,0.08972739999999998,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2005,1259247,1,1,,170464732,5755,Inconclusive,124375976.0,367.0,0.055157000000000005,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2006,1259248,1,1,,144208871,5755,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2007,1259248,1,1,,144213304,5755,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2008,1259248,1,1,,170464732,5755,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2009,1259310,1,1,,321946526,5755,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
2010,1259313,1,1,,50085972,5755,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
2011,1259318,1,1,,56463372,5755,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
2012,1259325,1,2,,336956228,5755,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
2013,1259344,1,1,,144204880,5755,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2014,1259355,1,1,,144204880,5755,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
2015,1259356,1,1,,144204880,5755,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
2016,1259364,1,1,,144208871,5755,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2017,1259364,1,1,,144213304,5755,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2018,1259364,1,1,,170464732,5755,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2019,1259365,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2020,1259365,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2021,1259365,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2022,1259366,1,1,,144208871,5755,Inconclusive,,,53.7079,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2023,1259366,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2024,1259366,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2025,1259367,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2026,1259367,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2027,1259367,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2028,1259368,1,1,,144208871,5755,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2029,1259368,1,1,,144213304,5755,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2030,1259368,1,1,,170464732,5755,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2031,1259369,1,1,,144208871,5755,Inconclusive,109731339.0,2737.0,0.6026,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2032,1259369,1,1,,144213304,5755,Inconclusive,109731339.0,2737.0,0.0306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2033,1259369,1,1,,170464732,5755,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2034,1259377,1,1,,144208871,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2035,1259377,1,1,,144213304,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2036,1259377,1,1,,170464732,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2037,1259378,1,1,,144208871,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2038,1259378,1,1,,144213304,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2039,1259378,1,1,,170464732,5755,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2040,1259379,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2041,1259379,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2042,1259379,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2043,1259380,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2044,1259380,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2045,1259380,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2046,1259381,1,1,,144208871,5755,Active,124375976.0,367.0,0.0851,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2047,1259381,1,1,,144213304,5755,Active,124375976.0,367.0,0.1536,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2048,1259381,1,1,,170464732,5755,Active,124375976.0,367.0,0.0944,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2049,1259382,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2050,1259382,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2051,1259382,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2052,1259383,1,1,,144208871,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2053,1259383,1,1,,144213304,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2054,1259383,1,1,,170464732,5755,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2055,1259384,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2056,1259384,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2057,1259384,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2058,1259385,1,1,,144208871,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2059,1259385,1,1,,144213304,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2060,1259385,1,1,,170464732,5755,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2061,1259386,1,1,,144208871,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2062,1259386,1,1,,144213304,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2063,1259386,1,1,,170464732,5755,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2064,1259387,1,1,,144208871,5755,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2065,1259387,1,1,,144213304,5755,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2066,1259387,1,1,,170464732,5755,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2067,1259388,1,1,,144208871,5755,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2068,1259388,1,1,,144213304,5755,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2069,1259388,1,1,,170464732,5755,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2070,1259390,1,1,,144208871,5755,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2071,1259390,1,1,,144213304,5755,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2072,1259390,1,1,,170464732,5755,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2073,1259391,1,1,,144208871,5755,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2074,1259391,1,1,,144213304,5755,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2075,1259391,1,1,,170464732,5755,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2076,1259392,1,1,,144208871,5755,Active,109731339.0,2737.0,7.58644,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2077,1259392,1,1,,144213304,5755,Inconclusive,109731339.0,2737.0,6.11306,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2078,1259392,1,1,,170464732,5755,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2079,1259393,1,1,,144208871,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2080,1259393,1,1,,144213304,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2081,1259393,1,1,,170464732,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2082,1259394,1,1,,144208871,5755,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2083,1259394,1,1,,144213304,5755,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2084,1259394,1,1,,170464732,5755,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2085,1259395,1,1,,144208871,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2086,1259395,1,1,,144213304,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2087,1259395,1,1,,170464732,5755,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2088,1259396,1,1,,144208871,5755,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2089,1259396,1,1,,144213304,5755,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2090,1259396,1,1,,170464732,5755,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2091,1259400,1,1,,170464732,5755,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
2092,1259401,1,1,,144208871,5755,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2093,1259401,1,1,,144213304,5755,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2094,1259401,1,1,,170464732,5755,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2095,1259402,1,1,,144208871,5755,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2096,1259402,1,1,,144213304,5755,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2097,1259402,1,1,,170464732,5755,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2098,1259403,1,1,,144208871,5755,Active,325495545.0,2101.0,26.9177,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2099,1259403,1,1,,144213304,5755,Inconclusive,325495545.0,2101.0,11.5149,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2100,1259403,1,1,,170464732,5755,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2101,1259404,1,1,,144208871,5755,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2102,1259404,1,1,,144213304,5755,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2103,1259404,1,1,,170464732,5755,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2104,1259406,1,1,,363920272,5755,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
2105,1259406,1,1,1.0,363920272,5755,Inactive,26638650.0,3778.0,0.0237503,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
2106,1259406,1,1,2.0,363920272,5755,Inactive,4758626.0,3779.0,0.00512472,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2107,1259406,1,1,3.0,363920272,5755,Inactive,5031823.0,10242.0,0.041096499999999994,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
2108,1259406,1,1,4.0,363920272,5755,Inactive,26051275.0,27345.0,0.0230219,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
2109,1259406,1,1,5.0,363920272,5755,Inactive,160410009.0,389816.0,-0.0308064,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2110,1259406,1,1,6.0,363920272,5755,Inactive,26638650.0,3778.0,0.0127993,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
2111,1259406,1,1,7.0,363920272,5755,Inactive,4758626.0,3779.0,0.0310973,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
2112,1259406,1,1,8.0,363920272,5755,Inactive,5031823.0,10242.0,0.019672799999999997,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
2113,1259406,1,1,9.0,363920272,5755,Inactive,26051275.0,27345.0,-0.012543799999999999,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
2114,1259406,1,1,10.0,363920272,5755,Inactive,5031823.0,10242.0,-0.0471272,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
2115,1259407,1,1,,363898930,5755,Inactive,,,,,CCRIS mutagenicity studies,Other,,
2116,1259408,1,1,,363894752,5755,Active,,,,,GENE-TOX mutagenicity studies,Other,,
2117,1259411,1,1,,363898930,5755,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
2118,1259415,1,1,,56463372,5755,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
2119,1259416,1,2,,375174565,5755,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2120,1259421,1,1,,375174565,5755,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2121,1259423,1,2,,354821483,5755,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2122,1259423,1,2,,355029360,5755,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
